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Abstract 
 
Pituitary-tumour transforming gene (PTTG), or human Securin, is an integral 
part of the spindle assembly checkpoint machinery in mitosis. It is often over-expressed 
in cancer, and is a prognostic marker for many cancer types.  PTTG mutational status, 
however, has not been explored until very recently. A Threonine-60 mutation in PTTG 
has recently been highlighted as inducing chromosomal instability, and increased 
invasiveness (Mora-Santos et al., 2013). This study hypothesises that phosphorylation at 
the Threonine-60 residue modulates PTTG degradation in mitosis, particularly in 
respect to its interaction with the anaphase promoting complex/cyclosome (APC/C). We 
aimed to investigate this hypothesis using both WT PTTG and PTTG forms mutated at 
the T60 residue through a variety of protein biochemistry techniques, predominantly 
investigating the interaction between the APC/C co activator Cdc20 and the 
ubiquitination potential of these proteins. Results indicate that mutation of the T60 site 
does not abrogate ubiquitination by the APC/C and increases binding to Cdc20 
compared to that of WT PTTG.  
  
	   4	  
Acknowledgements 	  
 I would like to thank Professor Chris McCabe for all his guidance and support 
throughout my time in his lab. Thank you to Dr Andy Turnell for his help and advice., 
and thanks also to all of the McCabe lab, particularly Vikki Poole, Bhavika Modasia 
and Gavin Ryan, for their encouragement and patience.  	   	  
	   5	  
Table of Contents 
 
1.0 INTRODUCTION ................................................................................................. 8 
1.1 THE CELL CYCLE ........................................................................................................... 8 
1.2 MITOSIS ....................................................................................................................... 11 
1.3 SPINDLE ASSEMBLY CHECKPOINT ............................................................................... 11 
1.3.1 The Anaphase Promoting Complex/Cyclosome ................................................... 13 
1.3.2  Separase and Securin ......................................................................................... 16 
1.3.3 The Mitotic Checkpoint Complex and Cdc20 ...................................................... 17 
1.4 HUMAN SECURIN - THE PITUITARY TUMOR-TRANSFORMING GENE ............................. 18 
1.5 PTTG MUTATIONS ...................................................................................................... 20 
1.7 AIMS AND OBJECTIVES ................................................................................................ 22 
2.0 MATERIALS AND METHODS ........................................................................ 23 
2.1 CELL LINES AND TISSUE CULTURE CONDITIONS .......................................................... 23 
2.1.1 Cell Lines ............................................................................................................. 23 
2.1.2 Tissue Culture ...................................................................................................... 23 
2.2 PLASMIDS AND TRANSIENT TRANSFECTIONS ............................................................... 24 
2.2.1 Plasmids ............................................................................................................... 24 
2.2.2 Transient Transfections ....................................................................................... 24 
2.2.3 Protein Harvesting ............................................................................................... 26 
2.3 TRANSFECTION AND ANTIBODY VALIDATION .............................................................. 26 
2.3.1 Sample Preparation ............................................................................................. 26 
2.3.2 SDS-PAGE ........................................................................................................... 27 
2.3.3Western Blotting ................................................................................................... 28 
	   6	  
2.4 CO-IMMUNOPRECIPITATION ......................................................................................... 30 
2.4.1 Cell Synchronisation ............................................................................................ 30 
2.4.2 Protein Harvesting and Co-Immunoprecipitation ............................................... 30 
2.4.3 SDS-PAGE and Western Blotting ........................................................................ 31 
2.5 IN VITRO STUDIES ......................................................................................................... 33 
2.5.1 L-α-[35S]-Methionine Radiolabelled in vitro Protein Synthesis ......................... 33 
2.5.2 Ubiquitination Assay ........................................................................................... 33 
2.5.3 GST-Pulldown Assay ........................................................................................... 35 
3.0 RESULTS ............................................................................................................. 36 
3.1 EXPRESSION OF PTTG MUTANTS IN TPC1 CELLS ........................................................ 36 
3.2 INVESTIGATING THE INTERACTION BETWEEN PTTG MUTANTS AND CDC20 ................ 36 
3.3 PTTG MUTANTS ARE SUBSTRATES FOR APC/C-DIRECTED UBIQUITIN LIGASE 
ACTIVITY ........................................................................................................................... 40 
3.4 INVESTIGATING THE INTERACTION OF THE PTTG MUTANTS AND APC/C SUBUNITS 
IN VITRO ............................................................................................................................. 43 
3.5 ANTIBODY VALIDATION .............................................................................................. 45 
4.0 DISCUSSION ....................................................................................................... 49 
5.0 REFERENCES .................................................................................................... 53 
 
  
	   7	  
List of Figures and Tables 
 
Figure 1: The Cell Cycle               9 
Figure 2: The Stages of Mitosis            10 
Figure 3: The Spindle Assembly Checkpoint          12 
Figure 4: The E1, E2 and E3 Ubiquitination Pathway         14 
Figure 5: PTTG Domain Map            21 
Table 1: List of Plasmids             25 
Table 2: List of Antibodies             29 
Figure 6: Transfection of WT and Mutant PTTG in TPC1 Cells          37 
Figure 7: Preliminary myc-Cdc20-PTTG Co-IP in Asynchronous HeLa Cell      38 
Figure 8: Replicate myc-Cdc20-PTTG Co-IP in Synchronised HeLa Cells        39 
Figure 9: Ubiquitination of APC/C Substrates Cyclin A and Cyclin B       41 
Figure 10: Ubiquitination of WT PTTG and mutant PTTG         42 
Figure 11: GST-Pulldown Assay of GST-APC3 and GST-Cdc20 with PTTG          44 
Figure 12: Validation of Day 53 Polyclonal T60 Phospho-Specific Antibody 
      Bleed               46 
Figure 13: Validation of Day 88 Polyclonal T60 Phospho-Specific Antibody 
       Bleed              47 
 
  
	   8	  
1.0 Introduction 
1.1 The Cell Cycle 
 
The cell cycle is a highly regulated, dynamic process. Normally, cells enter the 
cell cycle in response to cellular or environmental signals, and only undergo successful 
cell division if specific requirements and checkpoints are satisfied. Four main stages 
make up the cell cycle; G1 phase, where organelles and other cell components are 
duplicated; S phase, where DNA replication occurs; G2 phase, where the DNA is proof 
read and metabolic changes take place; and M phase, or mitosis, where the cell divides 
(Figure 1). 
 
The importance of strict control of the cell cycle has been understood to a 
certain extent for many years, with the first recorded observation of abnormal cell 
division in cancer made in 1914 by Theodor Boveri. Since then pioneering discoveries 
such as the Cdc (cell cycle division) proteins, cyclins and Cdks (cyclin dependant 
kinases), along with the presence of cell cycle checkpoints have helped understanding 
in this field grow exponentially (Nurse P., 1975; Evans et Al., 1983; Hartwell & 
Weinhart, 1989). 
 
The cell cycle has many regulatory points including, the G1 to S transition, the 
G2 to M phase transition and the Metaphase to Anaphase transition in mitosis. These 
regulatory processes are critical in the prevention of the abnormal cell division that can 
lead to the uncontrollable proliferation seen in cancer cells, and are particularly crucial 
to ensure cells undergo ‘normal’ mitosis. 
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Figure 1: The Cell Cycle 
Figure 1: The cell cycle. The different stages involved, in the cell cycle and the 
changes that occur during these stages (Source: University of Leicester (2013)) 
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Figure 2: The Stages of Mitosis 
 
 
 
  
Figure 2: The stages of mitosis. Individual stages of mitosis, and the alterations that 
occur (Source: University of Leicester (2013)) 
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1.2 Mitosis 
 
 Mitosis, or M phase, is comprised of five main stages – prophase, prometaphase, 
metaphase, anaphase and telophase (Figure 2). As cells enter prophase from G2 phase 
the nuclear envelope breaks down, chromosomes condense and spindle fibres begin to 
form. These spindle fibres begin to attach to kinetochores at the centromeres of the 
condensed chromosomes in prometaphase, and align upon the metaphase plate during 
metaphase (Ault & Nicklas, 1998) (Figure 2 and 3). At this point the spindle assembly 
checkpoint (SAC) must be satisfied for the cells to enter anaphase. For this to occur all 
chromosomes must be aligned upon the metaphase plate in a bi-orientated manner, and 
all chromosome kinetochores attached to spindle fibres (Reider et al., 1994; Reider et 
al., 1995). Once these requirements have been met the cells progress into anaphase 
where the Cohesion complex between sister chromatids is cleaved and sister chromatids 
move to opposing ends of the cell (Clute & Pines, 1999; Bagting et al., 2002) (Figure 2 
and 3). The nuclear envelopes reform in telophase, and ready the cell for cytoplasm 
division by cytokinesis (Figure 2). 
 
1.3 Spindle Assembly Checkpoint 
 
 The spindle assembly checkpoint (SAC) is the main cell cycle checkpoint in 
mitosis. Simplistically it monitors the attachment of kinetochores to the spindle fibres, 
and is sensitive enough to even detect a single unattached spindle (Reider et al., 1994; 
Reider et al., 1995). The tension exhibited upon the kinetochores and spindle fibres is 
an important signal indicative of spindle attachment, and until signals are received that  
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Figure 3: The Spindle Assembly Checkpoint 
  
Figure 3: The spindle assembly checkpoint. The stages of spindle fibre 
attachment, mitotic checkpoint control (MCC) formation, and the regulation of 
the anaphase promoting complex/cyclosome (APC/C) through the MCC. Upon 
attachment of spindle fibres to the kinetochores the APC/C is activated and cyclin 
B1 and securin are targeted for degradation, separase becomes activated, Cohesin 
is cleaved and sister chromatids are separated (Lara-Gonzalez, Westhorpe & 
Taylor, 2012). 
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all chromosomes are attached to spindle and aligned on the metaphase plate, the cell 
cycle arrests in metaphase (Ault & Nicklas, 1989). Upon successful chromosome 
alignment and attachment the proteins cyclin B1 and Securin are ubiquitinated by the 
APC/C (anaphase promoting complex/cyclosome) and as such are targeted for 
degradation. The protein Separase is activated and as a consequence cleaves the 
Cohesin bonds between sister chromatids thus allowing the cell cycle to enter anaphase 
and eventually exit mitosis (Figure 3) (Clute & Pines, 1999; Bagting et al., 2002).  
 
1.3.1 The Anaphase Promoting Complex/Cyclosome 
 
APC/C (anaphase promoting complex/cyclosome) function is essential for 
normal progression through the SAC (Holloway et al., 1993). The APC/C is a highly 
conserved, mega-Dalton, multi-subunit, E3 ubiquitin ligase (Reviewed by Harper et al., 
2002; Reviewed by Peters, 2006). It functions to regulate progression through the cell 
cycle by targeting cyclins and other cell cycle proteins such as Securin, for degradation 
by the proteasome (Irniger et al., 1995). E3 ubiquitin ligases are the final player of a 
multiple stage process in which proteins are targeted for degradation, and then degraded 
by the 26 S proteasome (Reviewed by Deshaies & Joazerio, 2009) (Figure 4). Initially 
ubiquitin molecules are activated, and bind to an E1 ubiquitin activating enzyme in a 
process that requires ATP (Reviewed by Deshaies & Joazerio, 2009) (Figure 4). Next 
the ubiquitin is transferred from the E1 enzyme to the ubiquitin conjugating, or E2, 
enzyme (Reviewed by Deshaies & Joazerio, 2009). The E2 enzyme – commonly 
UbcH10, or E2S in humans - then forms a complex with the APC/C and its substrate, 
enabling the ubiquitin molecule to be transferred to the protein substrate (Figure 4) (Jin  
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Figure 4: The E1, E2 and E3 Ubiquitination Pathway 
  
Figure 4: The E1, E2 and E3 Ubiquitination pathway. E1 ubiquitin-actvation 
enzyme binds to and activates ubiquitin (Ub), the Ub is then transferred to the E2 
ubiquitin-conjugating enzyme. The E3 ubiquitin-ligase binds to the substrate and to 
the E2-Ub complex, catalysing the transfer of Ub to the substrate. This cascade of 
reactions continues and a Ub chain forms on the substrate. This targets the substrate 
for degradation by the 26S proteasome. 
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et al., 2008). This process continues until a ubiquitin chain forms, and finally the 
substrate is targeted to and degraded by the 26S proteasome (Figure 4) (Reviewed by 
Deshaies & Joazerio, 2009). 
 
The APC/C has a vast range of substrates throughout many parts of the cell 
cycle, and requires two co-activators – Cdc20 and Cdh1 – in order to function fully 
(Passmore et al., 2003). These co-activators bind to the APC/C at different time points 
in the cell cycle and increase affinity for specific substrates, hence adding another layer 
of regulation to the ubiquitination  
process (Passmore & Barford, 2005). This increased affinity for particular substrates is 
caused by the ability of Cdc20 and Cdh1 to recognise different binding sites on the 
substrates. Substrates for ubiquitination by the APC/C typically contain either the 
destruction-box (D-box) – R-X-X-L-X-X-X-X-N/D/E – or the KEN-box – K-E-N-X-X-
X-D/N – motif, and some contain both (Glotzer et al., 1991; Pfleger & Kirschner 2000). 
Other putative motifs have been described such as the A-Box, CRY-Box and GxEN-
Box (Littlepage & Ruderman, 2002; Reis et al., 2006; Castro et al., 2003). D-box motifs 
are typically recognised by the APC/CCDC20 complex while KEN-box motifs are 
recognised by the APC/CCDH1 complex (Glotzer et al., 1991; Pfleger & Kirschner 2000; 
Burton & Solomon, 2001). In the case of Securin at the SAC it is recognised by 
APC/CCDC20 at its D-Box, which is located between residues 61-68 (Hillioti et al., 2001; 
Hagting et al., 2002). 
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1.3.2  Separase and Securin 
 
 The ratio of Separase to Securin at metaphase is what governs the separation of 
the sister chromatids and therefore progression into anaphase. Separase was identified 
in budding yeast - Saccharomyces cerevisiae – as Esp1 and fission yeast – 
Schizosaccharomyces pombe – as Cut1 (Ciosk et al., 1998; Funabiki et al., 1996). It is 
essential for sister chromatid separation during anaphase, and was found to contain a 
universally conserved histidine and cysteine residues typically found in cysteine 
peptidases (Funabiki et al., 1996; Nasmyth, Peters & Uhlmann, 2000). 
 
 Securin homologues Pds1 and Cut2 were first identified in S. cerevisiae and S. 
pombe respectively (Yamammoto, Guacci & Koshland, 1996; Cohen-Fix et al., 1996). 
Degradation of Securin via the APC/C was also found to be essential for cell cycle 
progression (Funabiki et al., 1996). The human homologue of Securin was discovered 
in a rat growth hormone secreting pituitary cell-line and is known as PTTG (pituitary 
tumor-transforming gene) (Pei & Melmed, 1997). 
 
Securin has a dual role in Separase regulation. Firstly it controls nuclear 
localisation of Separase (Jensen et al., 2001; Kumada et al., 2008; Zou et al., 1999; 
Jallepalli et al., 2001; Agarwal & Cohen-Fix, 2002). Secondly Securin binds Separase 
to inhibit its action upon the Cohesin complex that join sister chromatids together 
(Figure 3) (Coisk et al., 1998). Securin is a substrate of the APC/CCdc20 ubiquitin ligase 
complex. Formation of the MCC (mitotic checkpoint complex) with the APC/C co-
activator Cdc20 prevents the APC/C’s ubiquitin ligase activity therefore preventing 
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degradation of Securin (Figure 3) (Sudakin et al., 2001). When all kinetochores are 
bound to spindle fibres the MCC is released from Cdc20, and the APC/C targets 
Securin for degradation by the proteasome (Figure 3) (Hagting et al., 2002). In this 
manner the APC/C is able to regulate the activity of Separase until the requirements of 
the SAC have been satisfied (Cohen-Fix et al., 1996).  
 
1.3.3 The Mitotic Checkpoint Complex and Cdc20 
 
 The SAC is an incredibly complex system, involving many regulatory proteins 
and complexes. Much of the initial research into the SAC was carried out in yeast.  One 
of the primary discoveries was the identity of the proteins which made up the MCC 
(mitotic checkpoint complex). The MCC is an integral part of the SAC machinery and 
is comprised of several components. The mitotic arrest deficient (MAD1, MAD2 and 
MAD3/BUBR1) and budding uninhibited by benzimidazole (BUB1) proteins which 
make up the MCC were first identified in budding yeast, Saccahromyces cerevisiae 
(Hoyt et al., 1991; Li & Murray, 1991). Homologues of these highly conserved proteins 
were later identified in humans as MAD2, BUB3 and BUBR1 (Sudakin et al., 2001). 
Prior to mitosis proteins are recruited to the kinetochores to form the spindle fibre 
attachment sites (Musacchio & Salmon, 2007). Upon entering mitosis MAD2 
accumulates at unattached kinetochores in preparation for MCC formation (Musacchio 
& Salmon, 2007). The final component, and ultimately the target of the MCC, is the 
APC/C co-activator Cdc20. Cdc20 is bound by the MCC as the cells enter metaphase, 
inhibiting the action of the APC/C on Securin and cyclin B1 (Hwang et al., 1998; Kim 
et al., 1998).  
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  The order in which the MCC forms is unknown, but it is thought that a MAD2-
Cdc20 complex is required for BUB3 and BUBR1 to join the complex (Davenport, 
Harris & Goorha, 2006). It is also unknown whether the MCC binds Cdc20 in complex 
with the APC/C or in an unbound form (Fang et al., 1998). The binding of Cdc20 by the 
MCC prevents ubiquitination of the cyclin B1 and Securin therefore preventing 
progression into anaphase (Musacchio & Salmon, 2007). Upon binding of the 
kinetochores to the spindle fibres the MCC dissociates from Cdc20, and MAD2 levels 
around the kinetochores reduce 50-100 fold (Mussachio & Salmon, 2007). Following 
MCC dissociation from Cdc20, Securin is targeted for degradation by the APC/C, and 
the cell enters anaphase. 
 
1.4 Human Securin - the Pituitary Tumor-Transforming Gene 
 
Securin homologues Pds1 and Cut 2 were discovered in yeast in 1996 but the 
human form of Securin remained elusive until one year later a 202 amino acid long 
protein was found in a rat growth hormone secreting pituitary cell-line (Yamammoto, 
Guacci & Koshland, 1996; Cohen-Fix et al., 1996Pei & Melmed, 1997). This protein 
known as pituitary tumor-transforming gene (PTTG) was implicated in a range of 
cellular functions, and later found to be the human homologue of Securin (Pei & 
Melmed, 1997; Zou et al., 1999). After its initial discovery in a rat growth hormone 
secreting pituitary cell-line, PTTG was characterised in human foetal liver tissue (Pei & 
Melmed, 1997; Zhang et al., 1999). PTTG has since been identified as a proto-oncogene 
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and overexpressed in a wide range of tumours (McCabe & Gittoes, 1999; reviewed in 
Tfelt-Hansen, Kanuparthi  & Chattopadhyay, 2006). 
 
Aneuploidy leading to genome instability and mutation is a hallmark of cancer, 
and can be caused by disruption to chromosomal separation (Hanahan & Weinberg, 
2011; Lengauer et al., 1998). Cahill et al. (1998), first suggested aneuploidy in colon 
cancers was caused by aberrant SAC activity, and this has since been confirmed in a 
number of other cancers. Mutations in SAC checkpoint proteins generally seem to occur 
in the MCC components (Cahill et al., 1998). 
 
PTTG contributes to aneuploidy in cancer through abnormal expression levels 
(Chirstopoulou, Moore & Tyler-Smith, 2003). PTTG is overexpressed in a wide range 
of cancers including thyroid, breast, pituitary, ovarian, colorectal and lung  (Heaney et 
al., 2000; Solbach et al., 2004; Ogbagbriel et al., 2005; Zhang et al., 1999; Puri et al., 
2001; Heaney et al., 2000; Kakar & Malik, 2006). Overexpression is often associated 
with poor prognosis, metastasis, and reoccurrence; and has been suggested for use as a 
prognostic marker in multiple cancers such as thyroid, breast, pituitary, esophageal, 
glioma, hepatocellular carcinoma and squamous cell carcinoma of the head and neck 
(Boleart et al., 2003; Solback et al., 2004; McCabe et al., 2003; Shibata et al., 2002; 
Genkai et al., 2006; Fujii et al., 2006; Solbach et al., 2006). In recent years PTTG has 
been a target for anti-cancer therapies in both ovarian and lung cancer, therefore the 
biology behind this protein is particularly relevant for the development, and 
advancement of anti-cancer treatments (Yeakel & Kakar, 2008; Kakar & Malik, 2006). 
 
	   20	  
1.5 PTTG Mutations 
 
 A recent study mutated most of the 32 potential phosphorylation sites of PTTG 
from serine, threonine and tyrosine residues to glycine or alanine (Mora-Santos et al., 
2013). Of these mutants, Threonine-60-Alanine (T60A) increased PTTG half life to 30 
minutes from 18, was found to cause chromosomal instability using FISH (fluorescence 
in-situ hybridisation), and showed increased invasiveness through matrigel invasion 
assay and RT-PCR (real time – polymerase chain reaction) analysis of invasion related 
genes (Mora-Santos et al., 2013). Until recently PTTG mutations were thought to be 
extremely uncommon. However there has been an increase in the number of PTTG 
mutations found on the COSMIC (catalogue of somatic mutations in cancer) database of 
late (Forbes et al., 2008; Forbes et al., 2011). One such mutation is the Threonine-60-
Asparagine (T60N) residue found in a breast cancer tissue sample, which is interesting 
given the fuctional consequences of T60A mutation identified by Mora-Santos et al. 
(2013) (Stephens et al., 2012). 
 
The Threonine 60 (T60) residue of PTTG is situated immediately adjacent to the 
PTTG D-Box, which occupies amino acid residues 61-69 (Figure 5) (Mora-Santos et 
al., 2013). In yeast Securin degradation is regulated through phosphorylation of residues 
adjacent to the D-Box (Holt, Krutchinsky & Morgan, 2008). Phosphorylation of the 
yeast Securin homologue Pds1 by the kinase Cdk1 was found to prevent ubiquitination, 
whereas dephosphorylation by Cdc14 promoted ubiquitination of Pds1 (Holt, 
Krutchinsky & Morgan, 2008). Although PTTG does not contain Cdk1 binding sites in 
this area phosphorylation of the T60 residue by another kinase may lead to regulation in  
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Figure 5: PTTG Domain Map 
 
  
Figure 5: PTTG domain map. Location of KEN-box and D-box in PTTG. Red 
arrow indicates the location of the Threonine-60 residue. The D-box is located 
between residues 61-69. 
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202 1 
DNA*binding* SH3*BD*
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a similar manner to Pds1 in yeast, meaning that mutation to this residue may prevent 
this avenue of regulation. Mutation of the residue to an amino acid with vastly different 
properties - from polar threonine which is able to undergo phosphorylation to polar 
asparagine which is bulkier than threonine and not able to undergo phosphorylation - 
could also interfere with enzyme-substrate interactions, or have a spatial impact on the 
binding site, reducing the binding ability of PTTG to the APC/C. This could potentially 
explain the observations made by Mora-Santos et al., 2013. This project intends to 
expand upon these findings and to investigate how T60 mutations may influence PTTG-
APC/C interactions. 
 
1.7 Aims and Objectives 
 
Previous studies have suggested that mutation at the T60 residue of PTTG causes 
increased chromosomal instability and invasiveness. Given that this residue has also 
been shown to be mutated in a breast cancer we hypothesise that phosphorylation at the 
Threonine-60 residue modulates PTTG degradation by the APC/C in mitosis.  
 
We aim to investigate further the contribution of residue T60 in PTTG stability and 
in doing so: 
• Investigate interactions between WT PTTG and T60 mutants with the 
APC/C co-activator Cdc20 and APC/C subunit APC3 
• Determine whether T60 mutants can be ubiquitinated by the APC/C 
• Raise a polyclonal phospho-antibody against PTTG phosphorylated at the 
T60 residue 
	   23	  
2.0 Materials and Methods 
2.1 Cell Lines and Tissue Culture Conditions 
2.1.1 Cell Lines 
 
TPC1 cells were used as a model for transfection efficiency. TPC1s are a well-
characterised papillary thyroid carcinoma cell line commonly used in endocrine 
research (Saiselet et al., 2012).  
 
HeLa cells were used for co-immunoprecipitation, and ubiquitination assays. 
HeLas were isolated from cervical carcinoma cells positive for the HPV18 virus in 
1952, and became the first cell-line to be established in culture (Gey et Al., 1952).  
 
2.1.2 Tissue Culture  
 
TPC1 cells were cultured in RPMI 1640 (Sigma) and HeLa cells in DMEM/F-12 
(Gibco) both of which were supplemented with 10% (v/v) Foetal Bovine Serum 
(Gibco), 2 mM L-Glutamine and Penicillin and Streptomycin.  
 
Typically cells were grown in T75 flasks and passaged once confluent. Culture 
medium was aspirated and cells washed gently with PBS before adding 1ml Trypsin 
and incubating at 37OC for 5 minutes. After incubation 19 ml of culture medium was 
added, and cell density was calculated using a haemocytometer. Cells were then plated 
at the desired density onto new flasks. 
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2.2 Plasmids and Transient Transfections 
2.2.1 Plasmids 
 
A number of plasmids were used in transient transfections during this project. 
All constructs were inserted into the pcDNA3 (Invitrogen) vector, which was used as 
the vehicle only (VO) control for all transient transfections. The pcDNA3_PTTG 
plasmid (University of Birmingham, Birmingham, UK) was mutated to produce the 
mutant PTTG plasmids described below by Dr Weni Lu (University of Birmingham, 
Birmingham, UK), and the myc-Cdc20 and HA-APC3 plasmids were provided by Dr 
Andy Turnell (University of Birmingham, Birmingham UK) (Table 1). 
 
2.2.2 Transient Transfections 
 
TPC-1 or HeLa cells were plated onto 6-well tissue culture plates at a density of 
7.5x104 cells per well, or onto T25 flasks at a density of 1x106 cells per well, and 
incubated at 37OC overnight. The transfection reagents Fugene (Promega) and TransIT-
LT1 Transfection Reagent (Mirus-Bio) were used following the manufacturers’ 
guidelines. 
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Table 1: List of Plasmids 
 
Plasmid Construct Supplier 
pcDNA3 - Invitrogen 
pcDNA3_PTTG PTTG McCabe lab, University of 
Birmingham UK 
pcDNA3_PTTG_T60N PTTG T60N McCabe lab, University of 
Birmingham UK 
pcDNA3_PTTG_T60A PTTG T60A McCabe lab, University of 
Birmingham UK 
pcDNA3_PTTG_T60E PTTG T60E McCabe lab, University of 
Birmingham UK 
pcDNA3_Myc-Cdc20 Myc-Cdc20 Turnell lab, University of 
Birmingham UK 
pcDNA3_HA-APC3 HA-APC3 Turnell lab, University of 
Birmingham UK 
 
Table 1: List of plasmids used in all transient transfections and their suppliers. 
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2.2.3 Protein Harvesting 
 
Proteins were harvested using one of three methods. Co-transfected HeLa cells 
for co-immunoprecipitation were harvested using NETN buffer as described below 
(Section 3.4.2). 
 
Transfected TPC1 or HeLa cells were harvested from 6-well tissue culture plates 
using RIPA buffer (Tris-HCl (pH 7.4), 100 mM NaCl, igepal, 10% sodium 
deoxycholate, 100 mM EDTA) buffer, and protease inhibitor (Sigma). The medium was 
aspirated from the wells and washed once with 500 µl phospho-buffered saline (PBS). 
RIPA plus the protease inhibitor (150 µl) was added to each well and incubated at -
20OC for 30 minutes. The cells were then scraped using a cell scraper and transferred to 
a clean Eppendorf tube. Samples were sonicated on high power, for 30 seconds, twice 
and then centrifuged (12000 g, 10 minutes, 4OC). The supernatant was then transferred 
to new Eppendorfs and either used immediately or stored at -20OC. 
 
2.3 Transfection and Antibody Validation 
2.3.1 Sample Preparation 
 
Harvested protein sample concentrations were calculated using a BCA Protein 
Assay (Thermo Scientific). A standard curve was calculated using pre-prepared BCA 
protein standards in the range of 0-2 mg/ml BCA. Standards and samples (4 µl) were 
loaded onto a 96-well plate in duplicate, to which 80 µl of the BCA Protein Assay 
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reagent (10:1 dilution of BCA reagent A and BCA reagent B respectively) was added. 
The plate was then incubated at 37OC for 30 minutes, and the plate read at 562nm on a 
plate reader. 
 
Samples were typically prepared for SDS-PAGE and Western Blotting analysis 
at a concentration of 15 mg/ml in sample buffer (10% (w/v) DTT in Laemmli Buffer 
(BioRad)). They were then heated at 95OC for 5 minutes, and 37OC for 30 minutes 
before being loaded onto a SDS-PAGE gel. 
 
2.3.2 SDS-PAGE 
 
Small glass plates were fitted together following manufacturer’s guidelines. A 
12% (w/v) resolving gel (10 % (v/v) acrylamide, 0.1 M Tris, 0.1 M Bicine, 0.1 % (v/v) 
SDS, 0.3 % (v/v) N.N.N’N’ tetramethylethylenediamine-1,2-diamine (TEMED), 0.06% 
(w/v) ammonium persulphate (APS)) was poured in (7ml) and 3ml methanol added. 
Once set the methanol was poured off and a 5% stacking gel (5 % (v/v) acrylamide, 0.1 
M Tris, 0.1 M Bicine, 0.1 % SDS, 0.3 % (v/v) TEMED, 0.06% (w/v) APS) added with 
a 12 well comb and left to set. Once set the gels were placed into the electrophoresis 
tank (BioRad), the reservoir filled with running buffer (0.1 M Tris, 0.1 M Glycine, 0.1% 
(v/v) SDS) and the combs removed. To the first well 5µl of the dual protein standard 
(BioRad) was added, and the samples added to the remaining wells. The tank was 
assembled following manufacturer’s guidelines, and the samples were run at 70V for 20 
minutes through the stacking gel and 140V for 1 hour through the resolving gel. 
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2.3.3 Western Blotting 
 
PVDF (polyvinylidene fluoride) membrane (Millipore) was activated in 100% 
methanol, rinsed in distilled H2O and washed in transfer buffer. The SDS-PAGE gel 
was removed from the glass plates and transferred onto a layer of sponge and filter 
paper in a transfer cassette before the nitrocellulose membrane was placed on top. The 
cassette was completed with another layer of filter paper and sponge before being 
placed in a transfer tank filled with transfer buffer and an ice pack. The gel was left to 
transfer at 360 mA for 1 hour 15 minutes. 
 
Once transferred the membrane was removed from the tank and blocked for 1 
hour at room temperature with agitation in 5% (w/v) powdered milk in TBST (0.1 % 
(v/v) Tween80 in Tris Buffered Saline). After blocking the membrane was washed three 
times in TBST (10 minutes per wash) and incubated with agitation in the appropriate 
primary antibody in 5% powdered milk (w/v) in TBST (Table 2) at 4OC overnight. The 
membranes then underwent three more TBST washes and were incubated with agitation 
at room temperature with the appropriate secondary antibody in 5% powdered milk 
(w/v) in TBST (Table 2). Three more TBST washes were carried out. Pierce ECL 
(Thermo Scientific) was added to the membranes, which were then wrapped in cling 
film, exposed to photographic film and developed for visualisation. 
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Table 2: List of Anitbodies 
 
Target Antibody Dilution Factor Provider 
PTTG Monoclonal Mouse 
Anti-PTTG 
1:1000 NeoMarker, 
Freemont, California, 
USA 
T60 Phospho-PTTG Monoclonal Rabbit 
Anti-Phosphorylated 
T60 PTTG 
1:500 Covalab 
Myc-(Cdc20) Monoclonal 
Hybridoma Mouse 
Anti-Myc-(Cdc20) 
1:250 Turnell Lab, 
University of 
Birmingham, UK 
HA-(APC3) Monoclonal Mouse 
Anti-HA-(APC3) 
1:1000 Cambridge 
Biosciences, UK 
β -Actin Monoclonal Mouse 
Anti- β -Actin 
1:10000 Sigma-Aldrich 
Mouse IgG Polyclonal Rabbit 
Anti-Mouse HRP 
1:2000 Dako 
Rabbit IgG Polyclonal Goat 
Anti-Rabbit HRP 
1:2000 Dako 
Table 2: List of primary and secondary antibodies used in Western Blotting including 
dilution factors and providers. 
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2.4 Co-Immunoprecipitation 
2.4.1 Cell Synchronisation 
 
HeLa cells were transfected with the appropriate plasmids and incubated at 
37OC for 24 hours. Nocodazole (0.4 mg/ml in DMSO) was prepared at a concentration 
of 400 ng/ml in culture medium; 1 ml of this mix was added per T75 flask used. Cells 
were then incubated for 16 hours at 37OC. 
 
After 16 hours the cells underwent mitotic shake-off and were centrifuged (1200 rcf, 5 
minutes, 4OC). The supernatant was aspirated, and the pellets washed twice in culture 
medium (5 ml). The pellets were then re-suspended in culture medium plus 5 µM 
MG132 (from a 20 µM Mg132 stock), plated onto T25 flasks and incubated for 2 hours 
at 37OC. 
 
2.4.2 Protein Harvesting and Co-Immunoprecipitation 
 
Once cell synchronisation was complete the cells were washed twice with ice-
cold saline, and re-suspended in 900 µl NETN buffer (20 mM Tris (pH 7.5), 250 mM 
NaCl, 25 mM NaF, 25 mM β-glycerophosphate, 1 mM EDTA (pH 8.0), 1% (v/v) 
Nonidet P-40) on ice for 30 minutes with agitation. 
 
The cells in the NETN buffer were then transferred to a tight dounce hand 
homogeniser for lysis, and each sample was homogenised with 15 strokes. Samples 
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were then transferred to a new Eppendorf and centrifuged (13000 rpm, 5 minutes, 4OC). 
The supernatant was transferred to a new Eppendorf using a syringe, taking care not to 
disturb the lipid layer. At this point 25 µl of the lysate was retained for each sample and 
stored at -20OC. The samples were then incubated rotating overnight at 4OC with a 
monoclonal mouse hybridoma anti-myc-(Cdc20) antibody (Turnell Lab, University of 
Birmingham, Birmingham, UK) a 1:250 dilution. 
 
Protein G Sepharose beads (50 µl, GE Healthcare) were added to each sample 
and incubated, rotating, at 4OC for a further 2 hours. The samples were centrifuged at 
(13000 rpm, 1 minute, 4OC) to pellet the Protein G beads and the supernatant removed. 
The beads were washed in NETN (500 µl) 5-7 times, and the final wash aspirated using 
a syringe. To each sample 30 µl of sample buffer (10% (v/v) SDS, 9 M Urea, 50 mM 
Tris (pH 7.4), 100 mM β -mercaptoethanol) was added, and 25 µl sample buffer added 
to the cell lysate samples retained previously, in preparation for SDS-PAGE and 
Western blotting. 
 
2.4.3 SDS-PAGE and Western Blotting 
 
Co-immunoprecipitation (Co-IP), ubiquitination assay (section 3.5.2) and GST-
pull down (section 3.5.3) samples were all separated by SDS-PAGE on large 
acrylamide gels using the following protocol.  
 
Typically samples were loaded onto a 10% resolving gel (10 % (v/v) 
acrylamide, 0.1 M Tris, 0.1 M Bicine, 0.1 % SDS, 0.3 % (v/v) TEMED, 0.06% (w/v) 
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APS) with a protein ladder (Made in House). The electrophoresis tank was then 
assembled according to manufacturer’s guidelines, and running buffer (0.1 M Tris, 0.1 
M Bicine, 0.1% (v/v) SDS) poured into the reservoir. The samples were then run at 
continuous voltage of 18 V overnight  
 
Co-IP samples were then further analysed by established Western blotting 
techniques. The SDS-PAGE equipment was dismantled and the gel cut down to the 
appropriate size. Nitrocellulose membrane (PALL) was activated in transfer buffer (25 
M Tris, 192 mM glycine, 20% (v/v) methanol) and the Western blotting equipment 
assembled according to manufacturer’s guidelines. The transfer was then run at 280 mA 
for 5 hours. 
 
Membranes were washed once in TBST before blocking in 5% powdered milk 
(w/v) in TBST for 1 hour at room temperature. The Monoclonal Rabbit Anti-PTTG 
primary antibody (NeoMarker, Freemont, California, USA) was made at a 1:1000 
dilution factor in 5% powdered milk (w/v) in TBST and incubated with the membrane 
at 4OC with agitation overnight. Membranes were washed for 10 minutes in TBST three 
times, before incubation at room temperature for 1 hour in Protein G-HRP (BioRad) at a 
1:2000 dilution in 5% powdered milk (w/v) in TBST. After the final incubation 
membranes were washed three times in TBST for 10 minutes each. Pierce ECL 
(Thermo Scientific) was made up according to manufacturer’s guidelines and added to 
the membranes before wrapping in cling film. Blots were visualised by exposure to 
photographic film for the optimum exposure time, which were then developed using the 
X-OGraph Developer. 
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2.5 In vitro Studies 
2.5.1 L-α-[35S]-Methionine Radiolabelled in vitro Protein Synthesis 
 
Radiolabelled in vitro protein constructs of PTTG, PTTG T60N, PTTG T60A 
and PTTG T60E proteins were prepared using the appropriate plasmids, L-α-[35S]-
methionine (500µCi, Perkin Elmer) and a TNT T7-Coupled Rabbit Reticulocyte Lysate 
System (Promega) for coupled treanscription-translation following the manufacturer’s 
instructions. 
 
2.5.2 Ubiquitination Assay 
 
HeLa cells in T75 flasks were synchronised as described in section 3.4.1, and 
after undergoing mitotic shake-off were centrifuged (14000 rpm, 5 minutes). The 
supernatant was removed, and the cell pellet washed twice with culture media. Upon 
completion of the second wash the pellet was re-suspended in 10 mls of culture medium 
and incubated at 37OC for 1 hour. 
 
After incubation the cells were placed on ice, washed twice in ice-cold isotonic 
saline, and re-suspended in 12 ml APC/C lysis buffer (20 mM Tris (pH7.5), 100 mM 
NaCl, 20 mM β -glycerophosphate, 5 mM MgCl2, 0.2% (v/v) NP-40, 10% (v/v) 
glycerol, 1 mM NaF, 0.5 mM DTT) and left to stand for 5 minutes at 4OC. Cells were 
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then lysed using 15 strokes of a tight dounce homogeniser, waiting for 5 minutes, and 
repeating. The lysate was then centrifuged at 13200 rpm for 20 minutes at 4OC. 
 
The supernatant of the lysate was removed using a syringe, taking care not to 
remove the lipid layer, and divided equally between Eppendorfs so that for each 
ubiquitination assay there were two Eppendorfs of lysate, one positive and one negative. 
To each positive lysate Eppendorf the anti-APC3 antibody AF3.1 was added, and all 
lysate samples were incubated, rotating overnight at 4OC. 
 
Protein-G Sepharose beads (Sigma) were re-suspended in the APC/C lysate 
buffer at a 1:1 ratio; 20 µl equivalent of packed beads was added to each sample and 
was incubated, rotating at 4OC, for 2 hours. Samples were then washed in APC/C lysate 
buffer once, and a high salt buffer (BL) twice. To each sample 20 µl ubiquitination 
assay mix (5 mM MgCl2, 5 mM ATP, 10 mM creatine phosphatase, 350 Um-1 CPK, 
1.25 mg/ml ubiquitin, 20 µg/ml ubiquitin aldehyde, 50 µg/ml E1 [his-tagged 
recombinant hUB1], 40 µg/ml E2 [his-tagged recombinant UBch10 and UBE2S], in BL 
buffer) and 1 µl of the L-α-[35S]-methionine labelled proteins was added and incubated 
in a water bath at 37OC for 1 hour. Upon completion of the incubation SDS-PAGE 
sample buffer was added and samples separated by SDS-PAGE (as described in section 
3.4.3). The acrylamide gel was then dried, and visualised by autoradiography. 
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2.5.3 GST-Pulldown Assay 
 
The in vitro translated L-α-[35S]-methionine radiolabelled proteins (10 µl) were 
incubated with either GST-APC3 or GST-Cdc20 fusion proteins (10 µg) at 4OC for 1 
hour. Reaction volumes were then equalised by the addition of GST lysis buffer (1% 
(v/v) Triton X-100, 1mM EDTA (pH 8.0) in PBS). Packed glutathionine-agarose beads 
(Sigma) (20 µl) were added and the samples were incubated, rotating at 4OC for 1 hour. 
 
Following the incubation period the samples were washed three times with GST 
lysis buffer and a further two times with GST wash buffer (1mM EDTA (pH 8.0) in 
PBS).  Samples were eluted from the glutathionine-agarose beads with GST elution 
buffer (25 mM reduced glutathione in 50 mM Tris (pH 8.0)) and SDS-PAGE sample 
buffer (10% (v/v) SDS, 9 M Urea, 50 mM Tris (pH 7.4), 100 mM β -mercaptoethanol) 
added. Samples were then separated by SDS-PAGE (as described in section 3.4.3), the 
acrylamide gel dried, and then visualised by autoradiography. 
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3.0 Results 
3.1 Expression of PTTG mutants in TPC1 Cells 
 
Initially we assessed the transfection efficiency of the PTTG expression 
plasmids established in TPC1 cells (Figure 6). Wild type PTTG and the PTTG mutants 
were all successfully transfected and gave bands of the expected size (Figure 6). Myc-
Cdc20 was also successfully transfected to similar levels. However, transfection of the 
HA-APC3 plasmid was unsuccessful. Due to the time constraints of the project it was 
decided that analysis of APC3 interactions with WT (wild type) PTTG and PTTG 
mutants would not be explored by Co-IP.  
 
3.2 Investigating the interaction between PTTG mutants and Cdc20 
 
In order to investigate potential interactions between the WT and mutant PTTG 
proteins and Cdc20, HeLa cells were co-transfected with each of the PTTG plasmids 
and the myc-Cdc20 plasmid. Complexes were pulled-down with a monoclonal mouse 
hybridoma anti-myc antibody, and detected using the monoclonal mouse anti-PTTG 
primary antibody. Data collected from a preliminary Co-IP experiment used 
asynchronous cells and vehicle only transfected with myc-Cdc20 as a control (Figure 
7). Data suggested that WT PTTG and the PTTG mutants T60N, T60A and T60E 
interacted with with myc-Cdc20 to varying degrees, with interaction decreased in wild 
type PTTG compared to that seen in the mutants (Figure 7).  
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Figure 6: Transfection of WT and Mutant PTTG in TPC1 Cells 
 
 
	  
Figure 6: Transfection of WT and mutant PTTG in TPC1 cells. 
Transfection test of the PTTG plasmids expressing WT PTTG, PTTG T60N, 
PTTG T60A and PTTG T60E. All proteins were transfected successfully and 
expressed at levels higher than that of endogenous PTTG observed in the VO 
(Vehicle Only)  transfection. 
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Figure 7: Preliminary myc-Cdc20-PTTG Co-IP in Asynchronous HeLa Cells 
  
Figure 7: Preliminary myc-Cdc20-PTTG Co-IP in asynchronous HeLa 
cells. Protein complexes were pulled down with a monoclonal mouse 
hybridoma anti-myc-Cdc20 antibody and detected using a monoclonal mouse 
anti-PTTG primary antibody. The blot indicates that all of the PTTG proteins 
are able to interact with myc-Cdc20, with increased intensity in the T60N and 
T60E lanes. Interaction between PTTG and Cdc20 appears to be decreased in 
the WT PTTG lane. 
Myc-­‐Cdc20-­‐IP	  
PTTG	  Input	  
PTTG	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Figure 8: Replicate myc-Cdc20-PTTG Co-IP in Synchronised HeLa Cells  
Figure 8: Replicate myc-Cdc20-PTTG Co-IP in synchronised HeLa cells. 
Protein complexes were pulled down with a monoclonal mouse hybridoma anti-
myc-Cdc20 antibody and detected using a monoclonal mouse anti-PTTG primary 
antibody. (A) The first repeat in synchronised cells indicates that all of the PTTG 
proteins interact with myc-Cdc20, with increased intensity in the T60N and T60A 
lanes and decreased interaction in the PTTG and T60E lane. (B) The second repeat 
in synchronised cells suggests that all proteins are able to interact with myc-Cdc20 
at similar levels, with perhaps a slight increase in T60E. 
Myc-­‐Cdc20-­‐IP	   Myc-­‐Cdc20-­‐IP	  
PTTG	  
PTTG	  
Input	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The Co-IP was repeated twice more using synchronised cells. Nocadazole 
release was used to achieve synchronisation of cells during mitosis and optimise the 
amount of transfected myc-Cdc20 associated with the APC/C. Results differed between 
the two repeats, with one showing a similar trend to that seen in the asynchronous cells 
(Figure 8 A), and the other indicative of PTTG mutants T60N, T60E and T60A being 
able to bind to myc-Cdc20 at similar levels observed for normal PTTG (Figure 8 B). 
 
To assess these interactions in more detail, more appropriate controls need to be 
performed. Ideally the Co-IPs would have been run with samples incubated with and 
without the myc-Cdc20 antibody in order to highlight any non-specific binding. To 
further investigate the relationship between the PTTG mutants and the APC/C in vitro 
ubiquitination and GST-pulldown studies were carried out to investigate whether these 
mutants were substrates for the APC/C or interacted APC/C components. 
 
3.3 PTTG Mutants are Substrates for APC/C-Directed Ubiquitin Ligase Activity 
 
 To broaden our understanding of the interaction between the PTTG mutants 
with Cdc20, as suggested by the preliminary Co-IP data, the PTTG plasmids were used 
to synthesise in vitro L-α-[35S]-methionine radiolabelled proteins. The capacity of these 
radiolabelled proteins to undergo APC/C-directed ubiquitination was tested. To do this, 
the entire APC/C was precipitated from HeLa cells by immunoprecipitation with the 
AF3.1 APC3 antibody radiolabelled proteins were added to a mix containing E1, and 
E2 enzymes along with all the other essential components required for ubiquitination to   
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Figure 9: Ubiquitination of APC/C Substrates Cyclin A and Cyclin B  
 
  
Figure 9: Ubiquitination of APC/C substrates cyclin A and cyclin B 
Ubiquitination assay of L-α-[35S]-methionine radiolabelled known APC/C 
substrates cyclin A and cyclin B. The negative (-) and positive (+) markers 
indicate the absence and presence of the APC/C respectively. Ubiquitination 
of both cyclin A and cyclin B can be clearly seen in the positive lanes of the 
gel. 
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Figure 10: Ubiquitination of WT PTTG and Mutant PTTG  
 
  
Figure 10: Ubiquitination of WT PTTG and mutant PTTG. Ubiquitination 
assay of [35S]-Methionine radiolabelled WT PTTG, PTTG T60N, PTTG T60A 
and PTTG T60E proteins. The negative (-) and positive (+) markers indicate 
the absence and presence of the APC/C respectively. Ubiquitination of all 
PTTG forms can be seen.  
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take place. The assay took place with and without the presence of the APC/C to have 
positive and negative controls respectively, thus enabling the ubiquitination status of the 
proteins to be established. 
 
To further validate results radiolabelled Cyclin A and Cyclin B1 - known 
APC/C substrates – were used in the assay as positive controls to demonstrate 
successful ubiquitination (Figure 9). The assay was repeated twice with the in vitro 
translated PTTG and PTTG mutants  (Figure 10). The results from both assays are 
indicative of ubiquitination of PTTG, PTTG_T60N, PTTG_T60A and PTTG_T60E, 
and indicates that they are all viable substrates for the APC/CCdc20. 
 
3.4 Investigating the Interaction of the PTTG mutants and APC/C Subunits in vitro 
 
 The radiolabelled in vitro produced PTTG proteins were also used in GST 
pulldown experiments. Both Cdc20 and APC3 were available as GST tagged proteins 
providing an in vitro alternative to Co-IP experiments. This was a particularly useful 
tool for the evaluation of APC3 interactions with the different PTTG forms, as the 
plasmid expressing HA-APC3 was not successfully transfected for Co-IP studies to be 
carried out. 
 
 Preliminary findings indicated some interaction between the PTTG proteins with 
both GST-Cdc20 and GST-APC3 (Figure 11 B and C). The intensity of the bands 
varied  
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Figure 11: GST-Pulldown Assay of GST-APC3 and GST-Cdc20 with PTTG  
  
Figure 11: GST-pulldown assay of GST-APC3 and GST-Cdc20 with PTTG. (A) the 
PTTG proteins were incubated with GST alone (B) the PTTG proteins were incubated 
with GST-tagged APC3 (C) the PTTG proteins were incubated with GST-Cdc20  (D) 
indicates the starting levels of PTTG in each assay. 
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between PTTG forms, suggesting a higher interaction between wild type PTTG and the 
GST-APC3 and GST-Cdc20 proteins compared to that seen in the PTTG mutants 
T60N, T60A and T60E (Figure11 B and C). Non-specific interactions between the 
PTTG proteins and the GST tag were ruled out through incubation with the GST tag 
alone (Figure 11 A). The exposure time for the autoradiography was 120 hours (5 days) 
meaning that the intensity of the result were much lower levels than the starting amount 
of PTTG proteins (Figure 11 D), and perhaps if time constraints had allowed the assay 
would have been repeated to optimise the protocol. 	  
3.5 Antibody Validation 
  
During the course of this project we initiated the construction of a phospho-
specifc antibody to the phosphorylated form of the T60 residue in PTTG. This was 
carried out by Covalab over a course of 109 days using two female New Zealand white 
rabbits (rabbits 1223046 and 1223049 respectively). Three peptides were designed for 
use in the immunisation protocol in order to optimise the specificity of the antibodies 
being generated; a control peptide specific to the region surrounding the T60 residue in 
PTTG (FDAPPALPKATRKAL), a long phospho-peptide (FDAPPALPKATpRKAL) 
and a short phosphor-peptide (LPKATpRKA).  
 
 A bleed was taken from each rabbit on day 0 followed by immunisation with the 
control PTTG peptide. Injection with the long phospho-peptide was repeated on day 21,   
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Figure 12: Validation of Day 53 Polyclonal T60 Phospho-Specific Antibody Bleed 
 
  
Figure 12: Validation of day 53 polyclonal rabbit T60 phospho-specific 
antibody bleed. Antibody validation in HeLa cells using the day 53 bleeds 
membranes probed initially with the bleeds followed by re-probing with the 
Monoclonal Mouse Anti-PTTG antibody (A) Rabbit 1223046 day 53 bleed, with 
some binding seen at the 25 kDa marker correlating to where PTTG runs on a gel. 
(B) Rabbit 1223049 day 53 bleed, little to no binding seen at the 25 kDa marker. 
Both (A) and (B) show non-specific binding to a number of proteins. 
PTTG	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Figure 13: Validation of Day 88 Polyclonal T60 Phospho-Specific Antibody Bleed 
  
Figure 13: Validation of day 88 polyclonal rabbit T60 phospho-specific 
antibody bleed. Antibody validation in HeLa cells using the day 88 bleeds 
membranes probed initially with the bleeds followed by re-probing with the 
Monoclonal Mouse Anti-PTTG antibody (A) Rabbit 1223046 day 88 bleed, with 
little to no binding seen at the 25 kDa marker correlating to where PTTG runs on a 
gel. (B) Rabbit 1223049 day 88 bleed, some binding seen at the 25 kDa marker 
correlating to where PTTG runs on the membrane. Both (A) and (B) show non-
specific binding to a number of proteins. 
PTTG	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and the first injection with the short phospho-peptide was performed on day 42. The 
first test bleed was taken from each rabbit on day 53. Two more injections of the short 
phospho-peptides were carried out on days 63 and 77 before a second test bleed was 
taken on day 88. Specificity of the antibodies in the bleeds was tested on the transfected 
proteins PTTG, PTTG T60N, PTTG T60A, and PTTG T60E. (Figures 12 and 13 
respectively).  
 
 The specificity between the day 53 bleeds from the two rabbits varied. Both 
bleeds bound to several non-specific proteins (Figure 12). However, Rabbit 1223046 
showed some specificity for PTTG along the 25 kDa marker point, but not specificity 
for the phosphorylatable form of PTTG as binding was observed across all PTTG 
proteins (Figure 12 A). Little to no binding at the 25 kDa marker was observed with the 
1223049 bleed, compared to that by the PTTG antibody at this time point (Figure 12 B).  
 
The day 88 bleeds brought further variation to the previous findings. Whereas 
with the day 53 bleeds the most specificity for PTTG was observed in 1223046 the 
opposite was seen for the day 88 bleeds, with more specificity in 1223049 (Figure 13 
B). Again there was no real distinction between the phosphorylatable form of PTTG and 
the PTTG mutants T60N, T60A and T60E (Figure 13). Therefore two bleeds had low 
avidity for T60 phosphorylated-PTTG, or very low levels of T60 phosphorylated-
PTTG. Due to these findings, it was determined that an extension of the immunisation 
protocol from 109 days to123 days would optimise the development of this phospho-
specific antibody. 
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4.0 Discussion 
 
 PTTG over expression has been well catalogued in a number of cancers, 
however investigation into incidences of PTTG mutations in cancer has been explored 
very little (Heaney et al., 2000; Solbach et al., 2004; Ogbagbriel et al., 2005; Zhang et 
al., 1999; Puri et al., 2001; Heaney et al., 2000; Kakar & Malik, 2006). This project 
aimed to examine the effect of PTTG mutation at the T60 residue, following on from 
the recently published research by Mora-Santos et al. (2013) and hypothesised that 
phosphorylation at the Threonine-60 residue modulates PTTG degradation in mitosis. 
Co-IP studies evaluating interactions between myc-Cdc20, WT PTTG and the mutant 
PTTG forms suggested WT PTTG bound less strongly to myc-Cdc20 than the PTTG 
mutants. Ubiquitination assays demonstrated that the PTTG mutants were ubiquitinated 
to the same extent observed for WT PTTG, and a preliminary GST-assay indicated that 
the PTTG forms may interact with both Cdc20 and APC3. These findings indicate that 
mutations to the T60 residue is unlikely to regulate PTTG interaction with the APC/C in 
a negative manner. 
 
 The reduced binding of WT PTTG to myc-Cdc20 observed in the Co-IP 
experiments correlates with methods employed in the regulation of APC/C binding with 
other mitotic substrates. For example Cdc6 is a protein targeted for degradation by the 
APC/C early in the cell cycle (at G1 phase) to prevent pre-replicative complexes 
forming prior to S phase (Peterson et al., 2000). At the onset of S phase Cdc6 undergoes 
phosphorylation by the Cyclin E-Cdk2 complex, preventing the APC/C binding and 
therefore preventing degradation (Mailand & Diffley, 2005). In yeast a similar 
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regulatory mechanism is seen in the Securin homologue Pds1, whereby phosphorylation 
by Cdk1 resuces APC/C interactions, stabilising Pds1, therefore suggesting that such a 
mechanism in the human Securin homologue PTTG may not be so far-fetched (Holt, 
Krutchinsky & Morgan, 2008). 
 
 PTTG has one well established phosphorylation site at the Serine-165 residue 
(Ramos-Morales et al., 2000). Phosphorylation of this site is known to confer changes 
in PTTG activity (Boelaert et al., 2004). Although there are no known kinase concensus 
motifs in the region surrounding the T60 residue there are examples of regulation of 
other mitotic proteins through phosphorylation of non-consensus motifs by kinases 
(Mora-Santos et al., 2013; Colgan et al., 1998; Shah, Ghosh & Hunter, 2003). For 
example, Poly (A) Polymerase is regulated by cyclin B/Cdk1 at both consensus and 
non-consensus sites, as is Ribosomal S6 Kinase 1which is regulated by Cdk1 (Colgan et 
al., 1998; Shah, Ghosh & Hunter, 2003). 
 
 The results from this project have been slightly contradictory in so far as 
expecting that T60 PTTG mutations might lead to decreased APC/C interaction and 
hence increase stability of PTTG. The ubiquitination assay showed WT PTTG and the 
PTTG mutants were all readily ubiquitinated by the immunoprecipitated APC/C. 
Therefore this contradicts the increased stability of the T60A mutant compared to WT 
PTTG observed by Mora-Santos et al. (2013). However, along with PTTG over-
expression being a cause of abnormal cell division low expression levels of PTTG can 
also result in abnormal cell division; therefore the potentially increased affinity of the 
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mutant T60 PTTG proteins could result in similar effects as seen in cells with reduced 
PTTG expression levels (Yu et al., 2000). 
 
The increased stability observed by Mora-Santos et al. (2013) may be related to 
reduced binding of another E3 ubiquitin ligase. The SCF E3 ubiquitin ligase has been 
found to degrade phosphorylated PTTG (Gil-Bernabé et al., 2006). Gil-Bernabé et al. 
(2006) found that PTTG was a substrate for protein phosphatase 2A(PP2A), and that 
dephosphorylation of PTTG by PP2A induced stablility. The de-phosphorylation 
prevented ubiquitination of PTTG by the SCF E3 ligase in all stages of the cell cycle, 
independently of APC/C, therefore preventing it from being targeted for degradation by 
the 26S proteasome (Gil-Bernabé et al., 2006). This could explain the discrepancies 
between the results in this project and those observed by Mora-Santos et al. (2013) and 
warrants further investigation. 
 
 To further investigate these findings and to establish the contradictory results of 
this study and of Mora-Santos et al. (2013) a stability assay looking at PTTG levels over 
a time course at the SAC would need to be carried out. Mora-Santos et al. (2013) 
indicated that the T60A mutation led to increased half-life compared to that of WT 
PTTG. However, this was carried out in asynchronous cells where the APC/C complex 
would have been in complex with both Cdh1 and Cdc20. A stability assay in cells 
treated with nocodazole to halt cells at the metaphase to anaphase transition would 
ensure that the APC/C was in complex with Cdc20, and therefore provide a more 
accurate insight into stability of the PTTG mutants compared to that of WT PTTG. Co-
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IP experiments to investigate interaction of WT PTTG and the mutant PTTG proteins 
with PP2A or the SCF E3 ubiquitin ligase would also be of interest. 
 
 Although the Co-IP experiments suggest that WT PTTG binds less strongly to 
myc-Cdc20 than the PTTG mutants, the experiment needs to be optimised and more 
repeats carried out. Negative controls, where the Co-IP is carried out without the myc-
Cdc20 antibody, need to occur simultaneously with those incubated with the myc-
Cdc20 to rule out non-specific binding. The findings of the GST-Assay oppose the Co-
IP results, suggesting that WT PTTG binds more strongly to Cdc20 and APC3 than the 
PTTG mutants. This could be influenced by the proteins having been synthesised in 
vitro and thus not being in a phosphorylated form for the assay. The GST-assay was a 
preliminary study and therefore requires optimisation and repetition before more solid 
conclusions can be drawn from the data. Finally once the phospho specific PTTTG 
antibody has been fully developed and purified, it could be utilised to screen a wide 
range of primary tissue samples, and types of tissue samples to look incidences of T60 
mutational status in cancer.  
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Abstract 
 
 Vascular endothelial growth factor (VEGF) is a vital part of the decidualisation 
mechanism that prepares the endometrium for implantation of a blastocyst. Its integral 
role in the vascular reorganisation that occurs during decidualisation has long been 
established, however its role in decidualised stromal cells remains to be seen. It has 
been reported to be expressed in primary endometrial stromal and decidual cells, and 
more recently in an immortalised stromal cell line, St-T1b. This study hypothesises that 
VEGF is expressed upon decidualisation of stromal cells in response to cAMP 
stimulation, potentially through activation of the FOX1 transcription factor. We aimed 
to successfully decidualise St-T1b cells through progesterone and cAMP stimulation, 
examine VEGF expression at short decidual time points, and investigate potential 
VEGF gene regulation. Results suggest that VEGF expression increases upon 
decidualisation in a manner related to FOXO1 expression, and that VEGF expression by 
decidual cells has potential function implications. 
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1.0 Introduction 
 
It’s been 35 years since the first successful pregnancy from IVF (in vitro 
fertilisation) (Steptoe & Edwards, 1978). Since that time Assisted Reproduction 
Techniques, or ART, have advanced dramatically, yet there still remain discrepancies 
between IVF fertilisation rate and live birth rate following transfer of IVF embryos. A 
study by Malizia et al. (2009) examined data from 6000 IVF patients and established 
that the live birth success rate after three cycles of IVF treatment stood at 45% and at 
51% following six cycles of treatment. 
 
Success is influenced by many factors including maternal age, and embryo quality. 
Embryo screening protocols select the best –embryos, and therefore those most likely to 
progress to full term, are transferred (Puissant et al., 1987). Despite these measures 
being in place there remains a high rate of unsuccessful pregnancies, suggesting that 
other factors affecting the implantation process may contribute to infertility levels in 
these patients. It is therefore paramount to investigate the environment in which the 
transferred embryo must survive, in order to understand why the live birth rate 
following IVF treatment remains low. 	  
1.1 Menstrual Cycle 
 
 The menstrual cycle is comprised of two phases; the follicular phase, which 
precedes ovulation, and the luteal phase, which precedes menstruation. The cycle is 
controlled by several factors including; the female sex hormones Oestrogen and 
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progesterone, which predominantly control the cycle; follicle stimulating hormone 
(FSH) and luteinising hormone (LH) which are involved in ovulation; and inhibins A 
and B which are involved in regulation of FSH and LH (Johnson & Everitt, 2007). At 
low levels Oestrogen negatively regulates FSH and LH preventing follicle stimulation, 
and at high levels it positively regulates FSH and LH leading to follicular maturation 
and selection (Johnson & Everitt, 2007). Progesterone regulates oestrogen, causing it to 
fall and hence preventing negative regulation of FSH and LH by oestrogen (Johnson & 
Everitt, 2007). 
 
 The cycle begins with loss of the endometrium in response to falling oestrogen 
and progesterone levels (Figure 1) (Straussman, 1998; Jabbour et al., 2006). Stromal 
cells of the endometrium detect the decline in progesterone, triggering an enzyme 
cascade that results in influx of leukocytes, constriction of spiral blood vessels, 
expression of VEGF, and shedding of the endometrium (menstruation) (Straussman, 
1998). 
 
  The follicular phase follows menstruation. Follicles in the ovary are stimulated 
to grow by oestrogen. The endometrial cells begin to proliferate and the lining of the 
womb begins to grow (Mihm, Gangooly & Muttukirshna, 2010). The most dominant 
follicle induces an increase in oestrogen and inhibin A, which in turn lead to a dramatic 
rise in FSH and LH levels causing ovulation to occur (Figure 1). Upon ovulation 
oestrogen levels begin to decline, followed by an equally dramatic decrease in LH and 
FSH (Figure 1). At this point progesterone levels begin to increase and the follicular 
phase ends.  
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Figure 1: The Menstrual Cycle 
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Figure 1: The menstrual cycle. The various changes that occur in the menstrual 
cycle, highlighting follicular development, ovulation, and corpus luteum formation, 
corpus luteum degradation; endometrial cycling and hormonal changes in the 28 day 
cycle. (Where FSH = follicule stimulating hormone, and LH = lutenising hormone). 
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 The luteal phase begins with the formation of the corpus luteum from the 
ruptured dominant follicle left behind following ovulation, a rise in progesterone levels, 
and differentiation of the endometrium (Figure 1) (Mihm, Gangooly & Muttukirshna, 
2010). The corpus luteum expresses both inhibin A and oestrogen, however the high 
levels of progesterone inhibits the negative feedback effects of oestrogen on FSH and 
LH, ensuring that their levels remain low, and preventing further follicle stimulation 
(Figure 1). If fertilisation of the ovulated egg does not occur then the corpus luteum 
breaks down, both progesterone and oestrogen levels decline, and the luteal phase ends 
(Figure 1) (Straussman, 1998). This leads to the endometrium being shed and the cycle 
begins again (Figure 1). If fertilisation does occur progesterone persists at high levels, 
and the corpus luteum remains intact to prevent further follicular development, and loss 
of the endometrium (Straussman, 1998). 
 
1.2 Fertilisation and Early Embryo Development 
 
After ovulation occurs the oocyte is transported down the fallopian tube by cilia 
and peristaltic movements (Noorwood et al., 1978) (Figure 2). Spermatozoa have to 
overcome many barriers in their journey to the ovulated oocyte, with fewer than 1 in 
1,000,000 reaching the site of the oocyte (Johnson & Everitt, 2007). Sperm undergo 
several changes that affect their morphology and metabolism in order to be capable of 
fertilisation (Johnson & Everitt, 2007). These changes include; maturation in the male 
tract, particularly in the epididymis; hyper mobility through a process called 
capacitation; and the acrosome reaction which occurs within the female tract 
(Hinrichsen & Blaquier, 1980; Salicioni et al., 2007; Osman et al., 1989). 
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 Capacitation causes the spermatozoa to gain hyper mobility, and also enables 
them to detect the oocyte through olfactory sensors by chemotaxis (Johnson & Everitt, 
2007; Olsson & Laska 2010) (Figure 2). Upon locating the oocyte the spermatozoa bind 
to the zona pellucida which surrounds the ovulated oocyte. Here the spermatozoa 
undergo the acrosome reaction, prompted by signalling from the oocyte, which allows 
the sperm to digest a section of the ZP and enter the perivitelline space (Osman et al., 
1989). Here a spermatozoon is able to come into direct contact with the membrane of 
the oocyte. It binds, and fuses to the oocyte membrane and the nuclear content enters 
the oocyte’s cytoplasm (Reviewed by Kaji & Kudo, 2004). Simplistically, upon entry to 
the oocyte’s cyctoplasm the nuclear membrane breaks down, pro-nuclei form around 
both the male and female sets of chromosomes, and they gravitate towards one another 
to the centre of the oocyte (Johnson & Everitt, 2007). DNA synthesis occurs before the 
pronuclei breaks down, chromosomes align upon the metaphase plate and the first 
mitotic division occurs 24 hours after fertilisation, and the fertilised oocyte is now 
known as the conceptus (Johnson & Everitt, 2007) (Figure 2). 
 
 Throughout the early stages of development, the conceptus remains the same 
size, however the cell (blastomere) number within the conceptus increases with every 
division (Johnson & Everitt, 2007) (Figure 2). By the 8 cell conceptus a sequence of 
events leading to morphology changes begin. The morula forms, and just after the 
conceptus enters the uterus, around 4.5 days, it develops into a blastocyst (Johnson &  
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Figure 2: Early Embryo Development 
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Figure 2: Early embryo development. Diagram of the female reproductive organs, 
demonstrating the journey of the ovulated oocyte, fertilisation, and development of 
the conceptus prior to implantation. 
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Everitt, 2007) (Figure 2). Blastocyst development initiates differentiation of the 
blastomeres into either trophoblasts, which create a barrier to the uterine environment, 
or pluriblasts, which become the inner cell mass (Johnson & Everitt, 2007). At this 
point the blastocyst sheds the zona pellucida and prepares for implantation into the 
endometrium (Figure 2). 
 
1.3 Decidualisation  
 
 In order for implantation of the blastocyst to occur, changes to the endometrium 
must occur simultaneously to early embryo development. This creates a ‘window of 
receptivity’ when implantation can occur, where both the conceptus and the 
endometrium must have reached the correct stage of development at the same time 
(Psychoyos, 1976). This change to the endometrium is called decidualisation, where 
along with increased vascularisation, and an increase in immune cells, stromal cells 
differentiate into decidual cells in response to hormonal changes in the menstrual cycle 
(Johnson & Everitt, 2007). The process is vital to both the normal menstrual cycle and 
pregnancy, and occurs independently of the presence of a blastocyst (Mihm, Gangooly 
& Muttukrishna, 2010). 
 
 Upon decidualisation, endometrial stromal cells undergo morphological changes 
becoming less elongated and more rounded, metabolic changes occur, and the proteins 
expressed by the cells change (Oliver 1999; Brar 2001). In particular decidualised 
prolactin (dProlactin) and insulin-like growth factor binding protein 1 (IGFBP1) are 
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markers of decidualisation (Daly et al., 1983; Tseng et al., 1992; Telgmann & 
Gellerson, 1998).  
 
 The stromal to decidual cell transition requires both progesterone, and cyclic 
adenosine monophosphate (cAMP) (Brosens et al., 1999; Tankana et al., 1993; 
Telgmann & Gellerson 1998). Levels of cAMP are regulated by hormones such as 
pituitary gonadotrophins, prostaglandin E2 and relaxin (Tankana 1993; Gellerson & 
Brosens 2003). These hormonal signals initiate an enzyme cascade through G-coupled 
protein receptors (GPCR) (Telgmann et al., 1997) which activate andenylyl cyclase, 
producing cAMP (Telgmann et al., 1997). The cAMP activates downstream protein 
kinase A (PKA) signalling leading to activation of transcription factors involved in 
promoting the expression of decidual specific genes (Telgmann et al., 1997). If the 
cAMP stimulus is removed decidual cells revert back to stromal cells, the PKA pathway 
has to be maintained continuously in order for the decidual cells to remain differentiated 
(Telgmann et al., 1997). 
 
 Prolactin is a specific marker for decidualisation (Daly et al., 1983; Telgmann & 
Gellerson, 1998). The action of cAMP upon decidualising cells initiates prolactin 
expression in a number of ways. Firstly, cAMP via the PKA pathway, induces 
expression of CCAAT/enhancer binding protein β (C/EBPβ) a leucine zipper 
transcription factor (Landschulz, Johnson & McKnight, 1998; Pohnke, Kempf & 
Gellerson, 1999). C/EBPβ binds to a decidual-specific promoter region of prolactin and 
promotes its expression (Pohnke, Kempf & Gellerson, 1999). Secondly, cAMP also 
induces expression of FOXO1 a member of the FKHR (forkhead homologue in 
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rhabdomyosarcoma) transcription factor family (Davies et al., 1995). FOXO1 and 
C/EBPβ work in a synergistic manner at the decidual-specific prolactin promotor site to 
stimulate prolactin expression (Christian et al., 2002). 
 
 FOXO1 is involved in regulation of many integral cell functions including 
metabolism, and apoptosis (Reviewed by Katoh, 2004). Its intimate involvement in the 
apoptosis pathway means that it needs to be closely regulated so to promote survival. 
FOXO1 expression is induced upon differentiation of stromal cells to decidual cells 
(Labied et al., 2006). Its activity depends upon its localisation within the cell, which is 
highly regulated by the phosphoinositol-3 kinase (PI3K) pathway (Tang et al., 1999; 
Labied et al., 2006) (Figure 3). Normally, the PI3K pathway is stimulated leading to 
phosphorylation of the serine/threonine kinase Akt (Tang et al., 1999). Activated Akt, 
phosphorylates FOXO1, leading to exclusion from the nucleus and localisation in the 
cytoplasm preventing its function as a transcription factor (Tang et al., 1999). In 
decidual cells this process is inhibited by cAMP, which promotes nuclear localisation of 
FOXO1, however progesterone promotes the PI3K signalling pathway causing FOXO1 
to be localised to the cytoplasm (Christian et al., 2002; Labied et al., 2006) (Figure 3). 
This concept becomes easier to understand in the context of the menstrual cycle. During 
the luteal phase when progesterone levels are high the cytoplasmic localisation of 
FOXO1 promoted through the PI3K pathway is maintained (Labied et al., 2006) (Figure 
3). However, at the onset of menstruation, progesterone levels decrease and FOXO1 
remains localised at the nucleus through cAMP signalling initiating apoptotic pathways 
and endometrial breakdown (Brosens & Gellerson, 2006) (Figure 3). This is a prime  
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Figure 3: FOXO1 Regulation in Decidual Cells 
 
  
Figure 3: FOXO1 regulation in decidual cells. Regulation of FOXO1 by 
phosphorylation in response to stimulation by cAMP and progesterone (P4). 
(Source: Brosens & Gellerson, 2006). 
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example of the delicate balance of regulation that must occur within decidual cells to 
promote survival (Brosens & Gellersen, 2006). 
 
 Along with distinct changes at the cellular level, decidualisation also requires 
changes to the endometrial tissue organisation (Reviewed by Plasier, 2011). Amongst 
other changes, the endometrium undergoes extensive re-modelling of its vascular 
system in anticipation for implantation. This remodelling involves a number of 
angiogenic proteins including vascular endothelial growth factor A (from this point 
onwards VEGF). 
 
1.5 VEGF and Decidualisation  
 
 VEGF is an integral part of the mechanisms underlying the major reorganisation 
of vasculature during decidualisation of the endometrium (Plasier, 2011).  VEGF is 
strongly up-regulated by hypoxia in the endometrium to induce angiogenesis, and 
therefore is critical for implantation, and maintenance of the maternal-foetal blood 
supply (Sharkey et al., 2000; Plasier et al., 2011). It is thought that immune cells 
including machrophages, neutrophils uterine natural killer cells are a major source of 
VEGF in endometrial tissue (Charnock-Jones et al., 2000; Mueller et al., 2000; Li et al., 
2001; Jabbour et al., 2006). 
 
 The expression and function of VEGF in endometrial stromal and decidual cells 
is not fully understood. Studies using primary human endometrial stromal cells have 
shown that VEGF is expressed in response to both oestrogen and progesterone (Sugino 
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et al., 2002). Primary decidual cells also express VEGF in response to both hypoxia and 
stimulation by cAMP suggesting that pathways downstream of cAMP may also regulate 
VEGF expression (Popovici et al., 1999). The relationship between VEGF expression 
and decidualisation is an important one, as VEGF has been found to promote not only 
angiogenesis, but also cell survival (Spyridopoulos et al., 1996; Gerber et al., 1998; 
Gerber et al., 1998). For example in endothelial cells, VEGF inhibits TNF-α induced 
apoptosis, and also has been found to promote cell survival through the PI3K/Akt 
pathway (Spyridopoulos et al., 1996; Gerber et al., 1998). Additionally, in human 
umbilical vein endothelial cells VEGF induces expression of the antiapoptotic factors, 
Bcl-2 and A1 (Gerber et al., 1998). Primary decidual cells have been found to express 
the two VEGF receptors Flt1 and KDR, therefore it is possible that VEGF stimulates 
cell survival in decidualised endometrial stromal cells through similar mechanisms 
(Sugino et al., 2002). VEGF expression by decidual cells may also have an effect on the 
implanting trophoblast cells, particularly as they too express the VEGF receptors Flt1 
(fms-related tyrosine kinase 1) and KDR (kinase insert domain receptor) (Shore et al., 
1997). 
 
The recently characterised St-T1b stromal cell line produced through retroviral-
mediated human telomerase over-expression, can be differentiated by stimulation with 
progesterone and cAMP, and therefore provide an experimental model, alternative to 
primary endothelial stromal cells (Samalecos et al., 2009). A proteasome profile for St-
T1b cells has identified that VEGF is highly expressed in decidualised cells, and 
therefore is the ideal model for investigating VEGF expression in decidual cells 
(Schwenke et al., 2013). 
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1.7 Aims and Objectives 
 
Considering the plethora of literature concerning the function of VEGF in 
vascular remodelling in decidualisation, very little is known about the regulation and 
role of VEGF in endometrial stromal and decidual cells (Charnock-Jones et al., 2000; 
Plasier et al., 2011). Owing to its ability to function as an angiogenic factor in the 
endometrium, and its ability to stimulate cell survival mechanisms in endothelial cells, 
VEGF may elicit similar effects in differentiated stromal cells (Sugino et al., 2002).  In 
addition to inflammatory cells the decidualised stromal cells may represent a significant 
source of VEGF.   
 
We hypothesise that VEGF is up-regulated in endometrial stromal cells in 
response to cAMP stimulated pathways through FOXO1 activation. In this project the 
human St-T1b cell line was used as a stromal cell model to: 
• Establish and characterise decidualisation through treatment with 
progesterone and cAMP. 
• To investigate the pattern of VEGF expression following stimulation of 
cells with progesterone and cAMP stimulation andassess the potential 
involvement of FOXO1 in this process.  
• To determine whether conditioned medium from decidualised stromal 
cells influences the invasive properties of trophoblasts.    
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2.0 Materials and Methods 
2.1 Cell Lines and Culture Conditions 
 
2.1.1 Cell Lines 
 
The HEK-293 human embryonic kidney cells, were obtained from the ATCC, 
and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM), containing 10% foetal 
bovine serum (FBS), L-Glutamine and 50 I.U./ml Penicillin and 50  (µg/ml) 
Streptomycin (Pen/Strep) (Graham et al., 1977). HEC1-B cells are a human endometrial 
carcinoma cell line and were cultured in DMEM/Ham F-12, 10% FBS, L-Glutamine 
and Pen/Strep (Kuramoto, 1972). The HTR-8/SVneo (HTR-8) human trophoblast cell 
line was derived from first trimester trophoblasts immortalized using the SV40 large T 
antigen and kindly provided by Dr. Charles Graham (Department of Anatomy & Cell 
Biology, Queen’s University at Kingston, Ontario, Canada)(Graham et al., 1993). HTR-
8 cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium, 
containing 10% FBS, L-Glutamine, and Pen/Strep. The St-T1b human endometrial 
stromal cell line were established through retroviral-mediated human telomerase over-
expression (Samalecos et al., 2009) and kindly provided by Dr. Birgit Gellersen 
(Endokrinologikum, Hamburg, Germany). St-T1b cells were cultured in growth 
medium comprising DMEM/F-12, 10% FBS, I nM Oestradiol, 1 µg/ml Insulin, L-
Glutamine, and Pen/Strep.  
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2.1.2 Maintenance of Cell Lines 
 
Typically cells were grown in T75, or T25 flasks and passaged once confluent. 
Culture medium was aspirated and cells were washed gently with PBS (phosphate-
buffered saline) before adding 1ml Trypsin and incubating at 37OC for 5 minutes. After 
incubation with trypsin, 8 ml of culture medium was added, and cell density was 
calculated using a haemocytometer. Cells were then plated at the desired density. 
 
2.2 Plasmids and Transfections 
2.2.1 Plasmids 	  	  
Fragments (1.8, 2.9 and 4.7 Kb) of the human VEGF-A promoter, cloned into 
the pGL-2 luciferase reporter vector (Promega), were kindly provided by Dr Sheela 
Jayaraman (School of Immunity and Infection, University of Birmingham). The 
plasmids were transformed into E. coli (Bioline) and grown overnight on LB agar. 
Colonies were picked and grown overnight in 10 ml LB Broth, with agitation at 37OC. 
The cultures were scaled up to 100 ml LB Broth, and again grown up overnight with 
agitation at 37OC. The plasmids were extracted using an Endotoxin-free Maxi DNA kit 
(QIAgen) and concentration determined using a spectrophotometer. 
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2.2.2 Transient Transfection 
 
Transfections were carried out in HEK-293 and St-T1b cells primarily using 
ExGen500 (Fermentas), however transfection efficiency was tested using Fugene 6 
(Promega), Lipofectamine 2000 (Invitrogen), and JetPrime (Polyplus Transfection). 
HEK293 cells were plated at a density of 2x105 cells / well, and St-T1b cells at 1.2 x105 
cells /well onto 12-well plates and incubated overnight. Prior to transfection the growth 
medium was aspirated from the wells and replaced with 1 ml of fresh medium. For the 
St-T1b cells the growth medium was supplemented with 10 ng/ml FGF for St-T1b cells. 
Transfections were performed with 1 µg DNA following manufacturer’s guidelines and 
the DNA complexes added drop-wise to each well. Plates were then incubated for 48-72 
hours at 37OC. The medium in St-T1b cell transfections was aspirated after 24 hours of 
transfection and replaced with the appropriate medium, for the remainder of the 
incubation period. 
 
2.2.3 Luciferase Reporter Assays 
 
A Dual-Luciferase Reporter Assay (Promega) was used to determine VEGF 
promoter activity in transfected cells following manufacturer’s guidelines, and results 
were normalised to Renilla luciferase reading from the co-transfected pRL-CMV 
control plasmid. GFP expression levels were monitored through fluorescence 
microscopy. 
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2.3 Decidualisation and Analysis of St-T1b Cells 
2.3.1 Stimulation of Cells 
 
Decidualisation of St-T1b cells was induced as described by Samalecos et al. 
(2009). St-T1b cells were plated onto 6-well plates and allowed to grow to confluence.  
The growth medium was aspirated and cells were washed once with PBS.  The cells 
were treated with 1 ml of decidualisation medium (DMEM/F-12, 2% charcoal-stripped 
FBS, 1 µM MPA, 0.5 mM 8-Br-cAMP, Pen/Strep) . Control cells were incubated in 1 
ml per well of oestrogen containing medium (E2 medium) (DMEM/F-12, 10% 
charcoal-stripped FBS, 1 nM 17-Beta-Estradiol, 1 µg/ml Insulin, Pen/Strep).  
Conditioned medium was collected from cells after various time periods and stored at -
20OC.  
 
2.3.2 RNA Extraction  
 
Total RNA was extracted using an RNA Extraction Kit (Norgen). Cells growing 
on 6-well dishes were washed with 1 ml PBS and then incubated with 175 µl/well of 
RNA Lysis Buffer (Total RNA extraction kit, Norgen) for 5 minutes at room 
temperature. The lysate from the two wells was combined and the samples stored at -
20OC. 
 
Frozen samples were thawed on ice, and 600 µl of the lysate was loaded at a 
time onto a column and centrifuged (13,000 rpm, 1 minute) until all lysate had been 
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loaded onto the column. Flow through was discarded and the column was washed three 
times using 400 µl of the wash solution provided. Following the third wash the column 
was centrifuged once more at 13,000 rpm for 2 minutes to remove any excess wash 
solution from the column. The collection tube was discarded and replaced with a fresh 
RNase free Eppendorf, 50 µl of elution solution was loaded onto the centre of the 
column. The RNA was then eluted by one spin at 200 g for 2 minutes, followed by 
another spin at 14000 g for 1 minute. RNA concentration was measured on a 
spectrophotometer and then either used immediately to synthesise cDNA or stored at -
80OC. 
 
2.3.3 cDNA synthesis 
 
A stock solution of cDNA reaction mix (for one reaction; 1 µl Oligo (dT)18 
Primer, 1 µl 10 mM dNTP, 4 µl 5x RT buffer, 1 µl Ribosafe RNase inhibitor, 1 µl 
Reverse Transcriptase) was prepared using the cDNA synthesis kit (BioLine). RNA 
concentrations were normalised so that all cDNA reactions contained the same 
concentration of RNA and made up in PCR grade dH2O to have a total volume of 12 µl. 
To each RNA sample 8 µl of stock solution was added. The samples were then 
incubated at 45OC for 30 minutes, followed by 55OC for another 30 minutes. Samples 
were either used immediately for PCR or stored at -20OC. 
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Table 1: Table of Primers 
 
Primers Oligonucleotide Sequence (5’-3’) PCR 
Amplicon 
Size (bp) 
dProlactin – F 
dProlactin – 
R 
GAGACACCAAGAAGAATCGGAACATACAGG- 
TCGGGGGTGGCAAGGGAAGAA 
416 
IGFBP1 – F 
IGFBP1 - R 
TGCTGCAGAGGCAGGGAGCCC 
AAGGATCCTCTTCCCATTCCA 
378 
GAPDH – F 
GAPDH - R 
CAATGACCCCTTCATTGACC 
TTGATTTTGGAGGGATCTCG 
159 
 
Table 1: A table of all PCR primers used for decidualisation analysis and their 
sequences 
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Table 2: Table of PCR Conditions 
 
PCR Primer PCR Conditions 
dProlactin 44 Cycles: 94OC 45 sec, 57 OC 45 sec, 72 OC 45 sec 
IGFBP1 40 Cycles: 95 OC 30 sec, 63 OC 30 sec, 72 OC 60 sec 
GAPDH 35 Cycles: 95 OC 30 sec, 51 OC 30 sec, 72 OC 45 sec 
 
Table 2: PCR conditions and cycles used during amplification of cDNA products 
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2.3.4 PCR 
 
Decidualisation of St-T1b cells was confirmed by RT-PCR detection of 
decidualised Prolactin (dProlactin) and IGFBP1 with GAPDH as a control (Samalecos 
et al., 2009; Frettsome, 2011). PCR primers for dProlactin, IGFBP1 and GAPDH are 
shown in table 1.  Samples were prepared for PCR using 10 ul PCR reaction mix 
(BioLine), 1 ul cDNA, 0.5 ul of forward and reverse primers, and 8.5 ul of PCR grade 
H2O. The PCR reactions conditions are shown in table 2. 	  
2.3.5 VEGF ELISA 
 
Conditioned medium collected from stimulated St-T1b cells were analysed for 
VEGF levels using the Human VEGF DuoSet ELISA kit (R&D Systems) following the 
manufacturer’s guidelines. 
 
2.5 Spheroids 
2.5.1 Spheroid Production 
 
HTR8 spheroids were produced using the method of Korff & Augustin (1998). 
Methylcellulose (6 g) was autoclaved, and dissolved in 250 ml RPMI-1640 preheated to 
60OC for 20 minutes. A further 250 ml RPMI 1640 was added and the solution mixed 
overnight at 4OC. The methylcellulose solution was centrifuged (5000g, 2 hours, room 
temperature) and the supernatant aliquoted for use in spheroid production.HTR8 cells 
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were trypsinised, and the number of cells required (750 cells per well) added to a 20% 
methylcellulose, 80% RPMI-1640 growth medium. Of this stock solution 150 µl was 
added per well of a 96 well round bottomed suspension plate (Sarstedt) and incubated 
for 24 hours at 37OC for the spheroids to form. 
 
2.5.2 Sprouting Assays 
 
Sprouting assays were carried out in 24 well plates using 10-12 spheroids per 
well/condition. Spheroids were harvested using 200 µl pipette tips in an IVF tissue 
culture hood, and placed into 1 ml high serum medium (DMEM/F-12, 10% FCS, L-
Glutamine, Pen / Strep) in a 6 well plate. They were then washed in another 1 ml of 
high serum medium by transfer into another well of the 6 well plate. Fibrinogen (3 
mg/ml in DMEM/F-12) was prepared and 500 µl/well added to a 24 well plate.  
Spheroids (10-12/well) were transferred into the fibrinogen solution and 15 µl of 
thrombin was added and the plate was ‘swirled’ continuously to keep the spheroids 
suspension until the gel had set. 
 
To each well 500 µl of the appropriate medium was added, containing 10% 
protenin bovine blood trypsin inhibitor to prevent degradation of the fibrinogen. The 
spheroids were then incubated at 37OC and photographed at 24, 48, or 72 hours to 
monitor sprouting. 
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2.6 FOXO1 and VEGF Immunofluorescence  
2.6.1 Cell Culture on Microculture Slides 
 
Cells (2x104/well) were plated onto 8-well microculture slides (BD Falcon) in 
300 µl of normal growth medium and incubated at 37OC overnight. One well of HEC1B 
cells was plated, along with seven wells of St-T1b cells.  St-T1b cells were stimulated 
with decidualisation medium as described above (Section 3.3.1) at various times to 
coincide so that all wells on the slide were fixed at the same time.  
 
2.6.2 Fixing and Staining of Slides 
 
Cell fixation and staining was performed at room temperature Cells were fixed 
for 20 minutes in fixing solution (10 mM PBS (pH 7.4), 0.9% Formaldehyde, 0.8 g 
Glucose) washed once in PBS, incubated for 6 minutes in  100% Methanol, and then 
washed twice with PBS. Samples were blocked for 20 minutes in 5% normal goat 
serum in PBS, followed by incubation with the primary antibodies (Polyclonal Rabbit 
anti-FKHR 1:50 (Santa-Cruz Biotechnology), monoclonal Mouse anti-humanVEGF 
1:200 (R&D Systems) in 1% BSA in PBS). One control well was incubated without the 
primary antibodies. 
 
Cells were washed twice with PBS and then incubated, with the AlexaFluor 
(Invitrogen) secondary antibodies (Alexafluor 594 (red) Alexafluor 430 (green) 1.5% 
Goat Serum in PBS) for 1 hour in the dark. The culture chamber was removed and 
slides were mounted using DAPI (4’,6-diamidino-2-phenylindole) mounting medium. 
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Slides were visualised using fluorescence microscopy and photographed at x40 
magnification. 
 
2.5 Statistical Analysis 
 
 Statistical analysis was carried out using MicrosoftExcel. Where n number was 
less than 3 standard deviation about the mean was displayed on graphs, where n number 
was more than 3 standard error about the mean was used to show varience. Significance 
was analysed using a two-tailed, paired, student’s t-test and significance was displayed 
as shown in table 3.  
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Table 3: Statistical Significance Key 
 
P value Key 
P<0.05 * 
P<0.01 ** 
P<0.001 *** 
P<0.0001 **** 
 
Table 3: Statistical significance key  
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3.0 Results 
3.1 Decidualisation of St-T1b Cells 
 
 St-T1b cells were treated with either E2 medium or decidualising medium and 
harvested between 30 minutes and 72 hours, depending on the experiment. Initially 
there were difficulties with the St-T1b cells, they were not proliferating well or 
undergoing decidualisation. However, after a serum in the growth medium was changed 
and insulin was added to the condition of the cells vastly improved. In order to 
determine whether the cells were undergoing decidualisation the expression of three 
specific markers were examined (Daly, Maslar & Riddick, 1983; Christian et al., 2002; 
Salmelecos et al., 2009. Firstly, cell morphology was analysed by bright-field 
microscopy; secondly, FOXO1 expression and distribution was determined through 
fluorescent staining; and finally, dProlactin levels were determined by PCR.  
 
Figure 4 shows the characteristic change in morphology from an elongated, 
fibroblast-like appearance to a more rounded epithelial cell shape as the St-T1b cells 
decidualised. Cytofluorescent studies revealed the up-regulation and nuclear 
localisation of FOXO1 after 24 hours incubation in decidualisation medium compared 
with control cells non-decidualised medium, and PCR showed increased dProlactin 
expression in St-T1b cells (Figures 4 and 5 respectively). Having determined that the 
St-T1b cells were readily responding to decidualisation medium at the 24 hour time 
point they were further analysed for FOXO1 expression over time by fluorescent 
staining. 
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Figure 4: Morphological Change and FOXO1 Localisation in Decidualised St-T1b 
Cells   
  
Figure 4: Morphological change and FOXO1 localisation in decidualised St-
T1b cells.  Representative brightfield images (x 40 objective) showing characteristic 
St-T1b cell morphology following 3-day incubation in (A) E2 medium and (B) 
decidualisation medium. FOXO1 cytofluorescent staining of St-T1b cells incubated 
in (C) E2 medium and (D) decidualisation medium. FOXO1 staining  in (A) control 
and (B) decidualised St-T1b cells x 40 power.   
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Figure 5: Detection of dProlactin in Decidualised St-T1b Cells by PCR   
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Figure 5: Detection of dProlactin in decidualised St-T1b cells by PCR.  Agarose 
gel showing of dProlactin (416 bp)  and  GAPDH (159 bp) control with hyper ladder 
V DNA markers (lane 1) showing dProlactin levels in St-T1b cells stimulated with 
E2 medium (lane 2) or decidualisation medium (lane 3) for 24 hours. The 
decidualised St-T1b cells (lane 3) show expression, while no bands are seen in the 
non-decidualised cells (lane 2). 
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3.2 VEGF is up-regulated in endometrial stromal cells following decidualisation  
 
 Previous studies in this lab have indicated that VEGF is up-regulated in St-T1b 
cells 3-12 days following decidualisation.  To confirm these findings and determine 
whether increased VEGF expression occurs following shorter exposure of the cells to 
decidualisation medium the St-T1b cells were grown to confluence and then incubated 
with either E2 or decidualisation medium. Fresh medium was added to the cells 24 
hours prior collection at  24, 48 or 72 hours and VEGF levels assessed by ELISA. High 
levels of VEGF were detected in the decidualised cells compared to the control cells 
(Figure 6) within 24 hours of stimulation. 
 
 To establish the kinetics of VEGF release from St-T1b, cells were plated on a 12 
well plate (1.2 x 105/well) and grown to confluence. They were then treated with 
decidualisation medium, and conditioned medium collected following 30 minute, 2, 4, 
6, 10, and 24 hours incubation and VEGF levels were detected by ELISA. Figure 7 
shows the rapid induction of VEGF secretion following stimulation with decidualisation 
medium, which starts to accumulate rapidly between 6-10 hours.  
 
3.3 Localisation of VEGF and FOXO1 in decidualising St-T1b cells.  
 
To further investigate the induction of VEGF with FOXO1 St-T1b cells were 
treated with decidualisation medium for between 2 and 24 hours. As a negative control   
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Figure 6: Up-regulation of VEGF in St-T1b Cells Following Decidualisation 
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Figure 6: Up-regulation of VEGF in St-T1b cells following decidualisation. St-
T1b cells were incubated in decidualising medium (red bars) or growth medium 
(control - blue bars) and supernatants were collected over a 24 hour period at various 
time points. VEGF concentration was determined by ELISA (n=1) 
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Figure 7: Up-regulation of VEGF in Decidualised St-T1b Cells Over Time 
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Figure 7: Up-regulation of VEGF in decidualised St-T1b cells over time. 
VEGF concentration determined by ELISA in decidualised St-T1b cells over a 24 
hour time course. (n=1) 
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St-T1b cells were cultured in E2 medium for 24 hours, and HEC-1B cells used as a as a 
positive control. St-T1b cells treated with decidualisation  medium for 24 hours were 
used as a negative staining control. 
 
Following stimulation of the cells with decidualisation medium FOXO1 
expression increased and it became localised to the nucleus (Figure 8).  A clear 
difference in FOXO1 expression can be seen between the control and decidualised cells 
with the majority of cells showing strong nuclear staining by 24 hours (Figure 8). This 
correlates with its role as a transcription factor, initiating downstream effectors of the 
decidualisation process (Christian et al., 2002). Not all St-T1b cells underwent 
decidualisation (Figure 8). This is consistent with the complex layering of decidualised 
and non-decidualised cells seen in vivo  (Reviewed by Plasier, 2011).VEGF staining 
was low  in the HEC-1B cells which have been found to constitutively secrete VEGF by 
ELISA (> 100 pg/ml)  and some non-specific staining  was observed in the negative 
control making it difficult  to interpret the data (Figure 8). However, it was noted that 
the St-T1b cells that stained strongly for VEGF also showed strong nuclear expression 
of FOXO1 (Figure 8). The low VEGF expression in the HEC-1B positive control cells 
suggests that the antibody concentration may have been too low, or that VEGF is 
exocytosed out of the cell immediately after expression (Figure 8). To investigate this 
possibility conditioned St-T1b medium was produced and VEGF expression was 
detected by ELISA. 
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 Figure 8: Localisation of VEGF and FOXO1 in St-T1b Cells   
	   40	  
 
 
  
Figure 8: Localisation of VEGF and FOXO1 in St-T1b Cells. FOXO1 fluorescent 
staining (red), VEGF staining (green) and DAPI staining (blue) x 40 magnification. 
Positive control was HEC-1B cells, negative control St-T1b cells were incubated 
without primary antibodies, time in hours correlates to the time stimulated by 
decidualisation medium. 
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3.4 FOXO1 increases VEGF promoter activity  
 
 To investigate whether FOXO1 can regulate VEGF promoter activity, a plasmid 
encoding a constitutively active FOXO1 mutant under the control of the CMV promoter 
(pcDNA3_FOXO1), or empty vector control (pcDNA3) were co-transfected with 
VEGF promoter luciferase constructs and pRL plasmid (transfection control) into the 
HEK293 cells. Cells were transfected over a period of 48 hours, and VEGF promoter 
activity determined by dual luciferase reporter assay.  The results were were normalised 
to Renilla luciferase readings to account for any differences in transfection efficiency in 
each sample.  
. 
A greater than two-fold increase of VEGF promoter activity was detected in the 
presence of FOXO1 for all VEGF promoter reporter plasmids plasmids (Figure 9). This 
suggests that FOXO1 promotes VEGF expression by interacting with common sites in 
the first 1.8 Kb upstream of the transcriptional start site.   
 
3.5 Incubation of St-T1b cells with Decidualisation Medium decreases VEGF promoter 
activity. 
 
 The effect of stimulation of St-T1b cells with decidualisation or growth  medium 
on VEGF promoter activity  was investigated by a 24 hour transfection of the pGL2-
VEGF promoter-luciferase plasmids into St-T1b cells in duplicate, followed by 24 hour   
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Figure 9: FOXO1 Increases VEGF Promoter Activity 
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Figure 9: FOXO1 increases VEGF promoter activity. HEK-293 cells co-
transfected VEGF reporter-luciferase constructs (pGL2-VEGF-1.8, -2.9, and -4.7) 
and either pCDNA3-FOXO1 (red bars), or empty pCDNA3 plasmd (control – 
blue bars) and incubated for 48 hours. VEGF promoter activity was determined by 
dual luciferase assay. (n=2) 
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Figure 10: VEGF Promoter Activity in St-T1b Cells 
 
 
  
0	  
5000	  
10000	  
15000	  
20000	  
25000	  
30000	  
35000	  
plGf	  VEGF1.8	   plGf	  VEGF	  2.9	   plGf	  VEGF	  4.7	  
Non-­‐Decidualised	  Decidualised	  
Figure 10: VEGF promoter activity in St-T1b cells.  St-T1b cells were cells 
were transfected VEGF reporter-luciferase constructs (pGL-VEGF-1.8, -2.9, and -
4.7) and stimulated with either E2 medium (blue), or decidualisation medium (red) 
for 24 hours and dual luciferase assay. (n=2) 
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stimulation with either E2 or decidualisation medium. Again to account for transfection 
efficiency all transfections were carried out in the presence of the Renilla luciferase 
plasmid pRL, and data normalised to the Renilla luciferase activity. Surprisingly, a 
more than 2-fold decrease in VEGF promoter activity was observed in decidualised St-
T1b cells compared to non-decidualised cells (Figure 10). This may be due to the much 
lower transfection rate of St-T1b cells compared to HEK293s, as proliferation rate is 
much lower in decidualised St-T1b cells, or cAMP in the decidualisation medium may 
affect other signalling pathways that relate to VEGF expression (Samelocos et al., 
2009). 
 
3.6 HTR8 Sprouting Decreases with VEGF Stimulation 
 
 To determine the functional implications of VEGF expression by decidual cells, 
HTR8 cell spheroids were prepared. The HTR8 cells, a trophoblast cell line, were an 
ideal model for spheroid sprouting studies, and modelled the implanting blastocyst. 
Between 7-10 spheroids were implanted into fibrinogen, and incubated with low serum 
growth medium as a control, or low serum growth medium supplemented with either 20 
ng/ml VEGF or 100 ng/ml VEGF. Sprouting was monitored over a 72 hour time frame, 
and bright-field microscopy images at x10 magnification was photographed for analysis 
(Figure 11). The area of each spheroid (including sprouts) was measured for each image 
using Image J (Schneider, Rasbind & Eliceiri, 2012),  
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 Figure 11: HTR8 Spheroid Sprouting is reduced with VEGF 
  
Figure 11: HTR8 spheroid sprouting is reduced with VEGF. Bright-field 
microscopy images at x10 magnification of HTR8 spheroids taken at 24 hours, 
48 hours, and 72 hours of incubation with low serum growth medium control, 
and low serum growth medium control plus either 20 ng/ml VEGF or 100 ng/ml 
VEGF. Sprouting become apparent by 48 hours in the control and the 20 ng/ml 
VEGF medium, sprouting is not observed by 72 hours in the 100 ng/ml VEGF 
medium. 
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Figure 12: HTR8 Spheroid Sprouting is inhibited by VEGF   
Figure 12: HTR8 spheroid sprouting is inhibited by VEGF. Bar chart showing 
average area of HTR8 spheroids calculated using Image J, with standard error 
about the mean. Significant differences were calculated using a two-tailed, paired, 
students t-test. A p value of 0.00277 was observed between the spheroids 
incubated with low serum control and low serum control plus 20 ng/ml VEGF at 
48 hours, and of 0.00123 at 72 hours. A p value of 0.00277 was observed between 
the low serum control and the low serum growth medium plus 100 ng/ml VEGF at 
24 hours, of 6.02 x 10-5 at 48 hours and of 2.6x10-6 at 72 hours. 
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Figure 10 indicates that sprouting in both the low serum, and 20 ng/ml VEGF 
spheroids became apparent by 48, whereas the spheroids incubated with 100 ng/ml 
VEGF failed to produce sprouts by 72 hours. Each condition had an n number of 
between 7-11, the average area of the spheroids for each condition was calculated and 
plotted in Figure 12. Figure 12 shows a significant difference, where p<0.01, between 
the low serum control, and the 20 ng/ml VEGF spheroids at both the 48 hour and 72 
hour time point. A significant difference between the areas of spheroids incubated with 
the low serum growth medium and the 100 ng/ml VEGF medium can also be observed 
(Figure 12). With a p value of less than 0.01 at 24 hours, and a p value of less than 
0.0001 at the 48 hour and 72 hour time points, suggesting that high levels of VEGF may 
inhibit trophoblast invasion (Figure 12). To investigate this further spheroids were 
incubated with E2 growth medium, and conditioned day 9 decidual cell medium. 
 
3.7 HTR8 Sprouting Decreases when Incubated with E2 and Conditioned 
Decidualisation Medium 
  
 Following on from the HTR8 spheroid incubation with VEGF, spheroids were 
incubated with a low serum growth medium control, the E2 growth medium, and 
conditioned medium from day 9 decidual cells (Figure 13 and 14).  Figure 12 shows 
that in all conditions sprouting to a certain degree can be seen by 48 hours. 
 
 Analysis of the data indicates that there is a significant difference of p<0.01 
between the low serum control and E2 medium at 48 and 72 hours (Figure 14). A   
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Figure 13: HTR8 Spheroid Sprouting is reduced with Decidualised St-T1b 
Medium 
  
Figure 13: HTR8 spheroid sprouting is reduced with decidualised St-T1b 
medium. Bright-field microscopy images at x10 magnification of HTR8 spheroids 
taken at 24 hours, 48 hours, and 72 hours of incubation with low serum growth 
medium control, E2 growth medium and conditioned medium from day 9 decidual 
cells. Sprouting becomes apparent by 48 hours in the all conditions. 
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Figure 14: Decidualised St-T1b medium inhibits HTR8 Sphroid Sprouting 
  
Figure 14: HTR8 spheroid sprouting is inhibited by decidualised St-T1b medium. 
Bar chart showing average area of HTR8 spheroids calculated using Image J, with 
standard error about the mean. Significant differences were calculated using a two-
tailed, paired, students t-test. A p value of 0.00269 was observed between the 
spheroids incubated with low serum control and E2 growth medium VEGF at 48 
hours, and of 0.00552 at 72 hours. A p value of 0.00507 was observed between the 
low serum control and the conditioned medium from day 9 decidual cells at 48 hours 
and of 3.98x10-9 at 72 hours. 
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significant difference between the low serum control and conditioned medium can also 
be observed, with a p value of less than 0.05 at 48 hours and less than 0.0001 at 72 
hours (Figure 14). This also supports the notion that VEGF may act to regulate 
trophoblast invasion. 
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4.0 Discussion 
 
 VEGF is integral for vascular remodelling during decidualisation, and for 
sustaining blood supply to the growing embryo (Plasier et al., 2011). Expression has 
been reported in primary endometrial stomal cells, primary endometrial decidual cells, 
and the stromal cell line St-T1b when under decidualisation conditions (Sugino et al., 
2002; Popovici et al., 1999; Schwenke et al., 2013). Along with being an angiogenic 
factors, it has also been reported to play a role in induction of cell survival pathways 
(Spyridopoulous et al., 1996; Gerber et al., 1998; Gerber et al., 1998). Much is known 
about VEGF’s function in vascular remodelling, however very little is known about its 
significance, and thus implications of its expression in decidual cells. This project 
hypothesised that VEGF is expressed upon decidualisation of stromal cells in response 
to cAMP pathways; results support this hypothesis and suggest potential functional 
consequences of VEGF expression. 
 
 The St-T1b endometrial stromal cell-line was used as a model for decidual cells, 
as they decidualise upon stimulation with progesterone and cAMP containing medium 
(Samaleacos et al., 2009). The low n number for some of the experiments can be 
explained by the difficulty in inducing decidualisation at first. The cells were 
proliferating very slowly, and not reaching confluence when expected, therefore 
slowing down the rate at which experiments could be carried out at. This problem was 
remedied with the addition of insulin, and new foetal bovine serum (Sigma) after which 
the condition of the cells improved vastly and readily underwent decidualisation. 
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 As mentioned previously, past studies have observed changes in VEGF 
expression levels between primary endothelial stromal and decidual cells (Sugino et al., 
2002; Popovici et al., 1999). Although high levels of VEGF have also been recorded in 
decidualised St-T1b cells a direct comparison of VEGF expression in non-decidualised 
and decidualised St-T1b cells has not been explored (Schwenke et al., 2013). Detection 
of VEGF by ELISA in conditioned medium found that VEGF levels rapidly increase 
after 24 hours of stimulation with decidualisation medium. Increases were also observed 
at 48 and 72 hours, but to a lesser extent. This decrease may have been because the cells 
became exhausted after consecutive stimulation with cAMP and progesterone over 24 
hours. Ideally the ELISA would be repeated at least two more times to get an n number 
of 3, however due to the difficulties at the beginning of the project this was only carried 
out once. However, the short time course experiment measured by ELISA, and 
previously unpublished ELISA data carried out within the lab also support these 
findings. These results correlate to the large induction of VEGF expression found in 
immune cells that localise to the endometrium during decidualisation (Charnock-Jones 
et al., 2000; Mueller et al., 2000; Li et al., 2001; Jabbour et al., 2006). 
 
 In order to investigate a potential relationship between FOXO1 and VEGF 
expression fluorescence staining was carried out. The increase in FOXO1 staining in 
decidual St-T1b cells compared to non-decidualised cells is supported in the literature, 
and the nuclearisation of FOXO1 in response to cAMP stimulation could also be 
observed (Christian et al., 2002; Labied et al., 2006). The VEGF staining proved more 
difficult to interpret. Whereas the FOXO1 positive and negative controls were to a good 
standard, the positive and negative controls for VEGF were poor. Little staining could 
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be observed in the positive control, and non-specific staining could be seen in the 
negative control. Despite this, in the merged images VEGF staining tended to be 
localised to cells that also had nuclear FOXO1 staining, and also appeared to be 
vesicular in nature. The low VEGF staining in the positive control could be explained if 
VEGF is rapidly secreted, the staining protocol could be improved in the future by 
addition of sodium azide to the fixative solution in order to retain any secretory proteins 
within the cells during the washes.  
 
 Luciferase reporter assays in HEK293 cells showed a large increase in 
exogenous VEGF expression when co-transfected with FOXO1. This supports 
unpublished data from the lab in which cells infected with a constitutively active 
FOXO1 adenovirus rapidly produced high levels of VEGF. Suggesting a role for 
FOXO1 in VEGF expression. However, this was not supported by the luciferase 
reporter assay carried out in non-decidualised and decidualised St-T1b cells. Exogenous 
VEGF levels decreased in decidualised cells, which is contradictory to the previous 
findings. This may have been due to other factors stimulated by cAMP, or because St-
T1b cell proliferation was stimulated by FGF during transfection and may have 
interfered with cellular pathways. Ideally the transfection process would be optimised, 
and negative control wells without stimulation with FGF used to rule out any 
interference. Another possibility could be that like prolactin, VEGF may have an 
alternative promoter site specific to decidualisation (Pohnke, Kempf & Gellerson, 1999; 
Christian et al., 2002). The VEGF gene is 16.3 kb, the plasmids used in the luciferase 
reporter assays only had a maximum VEGF insert of 4.7 kb, therefore there may be 
other promoter regions in the remaining 11.6 kb. 
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 Together, the HEK293 luciferase assay results and the fluorescence staining are 
indicative of a relationship between nuclear localisation of FOXO1 and VEGF 
expression. Furayama et al. (2004) described FOXO1 as vital for VEGF mediated 
vascularisation during development. Distinct morphological differences were observed 
in endothelial cells of FOXO1 deficient mice. The mice were not viable, and had 
irregular vascular development caused by abnormal VEGF expression in response to the 
FOXO1 knock out (Furayama et al., 2004). More recently, FOXO1 was found to bind 
the VEGF-A promoter and regulate gene expression directly in Pancreas β-Cells, which 
supports the hypothesis made by this study that VEGF expression in decidual cells may 
be regulated by cAMP induced mechanisms, such as FOXO1 (Kikuchi et al., 2012). 
 
 To determine functional implications of VEGF expression, HTR8 spheroids 
were used as a model for the outer layer of trophoblasts of the blastocyst. During 
implantation trophoblasts adhere to the endometrium, and implant in an invasive 
manner (Plasier et al., 2011). Trophoblast cells are known to secrete VEGF to promote 
angiogenesis at the site of implantation, however the effects of externally produced 
VEGF upon stromal cells have not been studied in any great detail (Plasier et al., 2011). 
Spheroids were incubated with a control low serum medium and either increasing 
concentrations of VEGF, or with either non-decidualising E2 medium, or day 9 
decidualisation conditioned medium. Both concentrations of VEGF inhibited sprouting 
of HTR8 cells at the 48 and 72 hour time points to a level of statistical significance. 
This was particularly evident in the spheroids incubated with 100 ng/ml VEGF, which 
gave a p value of 2.6 x 10-6 by the 72 hour time point. Similar decreases were observed 
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in the spheroids incubated with either E2 growth medium, or day 9 decidualisation 
conditioned medium. A p value of 3.98 x 10-9 was observed at 72 hours for the 
spheroids incubated with the day 9 decidualisation conditioned medium. This data 
suggests a functional role for VEGF other than that observed in angiogenesis and 
perhaps is involved in regulation of invasion processes. This is supported by the 
expression of VEGF receptor Flt1 and KDR by trophoblast cells (Shore et al., 1997). 
 
In respect to future research avenues, ideally RT-PCR to analyse mRNA levels 
of VEGF during decidualisation would be carried out, to establish whether the high 
concentration of VEGF detected by ELISA was due to expression or excretion of VEGF 
stores within the cell. Chromatin Immunoprecipitation (or ChIP) analysis of VEGF and 
FOXO1 would elucidate whether FOXO1 regulates VEGF expression in a direct 
manner. Ultimately, stable knock down of FOXO1 in St-T1b cells with siRNA would 
create an ideal negative control and would provide a more accurate way of assessing the 
effect of FOXO1 on VEGF expression. In respect to functional analysis, invasion assays 
using matrigel inserts may provide a way to assess spheroid invasion in response to 
VEGF or conditioned medium.  The findings of this project support the hypothesis 
that VEGF expression increases with decidualisation of St-T1b cells, and is potentially 
regulated by FOXO1. In respect to the literature, the high VEGF expression by the 
decidualised St-Tb cells along with the known expression of Flt1 and KDR by primary 
decidual cells could implicate VEGF as an autocrine survival signal (Shore et al., 1997). 
The response of the HTR8 spheroids to incubation with VEGF, and conditioned 
decidual medium suggest possible functional mechanisms. This project has only 
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scratched the surface of the role of VEGF in decidualisation and further research is 
required to elucidate its role, and the mechanisms by which it functions. 
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